Heterocyclic compounds having antitumor activity and uses thereof

Novel heterocyclic compounds are developed to address the limitations of existing SOS1 inhibitors by enhancing binding affinity and specificity, providing a promising therapeutic approach for SOS1-mediated diseases.

JP2024545236AActive Publication Date: 2024-12-05CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024535751
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-07
Filing Date
2022-12-16
Publication Date
2024-12-05
Estimated Expiration
2042-12-16

AI Technical Summary

Technical Problem

Current SOS1 inhibitors face challenges in reaching commercialization due to inadequate efficacy and pharmacokinetic properties, necessitating the development of novel compounds that can effectively target SOS1 protein to inhibit RAS activation in tumors.

Method used

Development of heterocyclic compounds represented by specific formulas (A, I, II, III, IV) that act as SOS1 inhibitors, featuring various substituents and ring structures to enhance binding affinity and specificity for SOS1, thereby inhibiting its interaction with RAS proteins.

Benefits of technology

The novel heterocyclic compounds demonstrate potential as effective SOS1 inhibitors, offering improved therapeutic efficacy against SOS1-mediated diseases by targeting SOS1 protein interactions with RAS family proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545236000001_ABST
    Figure 2024545236000001_ABST
Patent Text Reader

Abstract

The present invention provides a series of compounds, and their stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates (e.g., hydrates) or isotopic derivatives. The compounds of the present invention have a triheterocyclic structure (e.g., the structure shown in formula (A)), which is a novel structure and provides a new direction for the development of SOS1 inhibitors. In vitro enzyme activity inhibition studies have shown that these compounds have strong inhibitory effects on SOS1, and are promising compounds for preventing and / or treating SOS1-mediated diseases. Moreover, these compounds show obvious inhibitory activity against NCI-H358 cell proliferation. The present invention also provides a specific synthesis method, which is simple in process, easy to operate, and conducive to large-scale industrial production and use. [Formula 1] TIFF2024545236000154.tif54161
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention claims priority to a patent application filed in China on December 17, 2021, entitled "Heterocyclic Compounds with Antitumor Activity and Use Thereof" with application number 202111561282.9, and a patent application filed in China on June 7, 2022, entitled "Heterocyclic Compounds with Antitumor Activity and Use Thereof" with application number 202210634934.5, both of which are incorporated herein by reference in their entireties.

[0002] The present invention relates to the field of medical technology, and in particular to compounds as SOS1 inhibitors, as well as compositions, methods of preparation and uses of said compounds. [Background technology]

[0003] Currently, three genes in the RAS family are known: KRAS (Kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral oncogene homolog), and HRAS (Harvey rat sarcoma viral oncogene). RAS family proteins are small GTPases and were the first oncogenes identified in human tumors. RAS family proteins have weak intrinsic GTPase activity and slow nucleotide exchange rates. For example, binding of NF1 GTPase-activating protein (GAP) increases the GTPase activity of RAS family proteins.

[0004] Mutations in RAS proteins are closely related to tumorigenesis, and the type of RAS mutation varies depending on the tumor type. In human tumors, KRAS mutations (e.g., amino acids G12, G13, Q61, and A146) are the most common, accounting for approximately 85% of tumors, while NRAS (e.g., amino acids G12, G13, Q61, and A146) and HRAS (e.g., amino acids G12, G13, and Q61) account for 12% and 3%, respectively. Alterations in RAS family proteins (e.g., mutations, overexpression, and gene amplification) have been described as mechanisms of resistance to anticancer drugs, such as the EGFR antibody cetuximab and panitumumab, and the EGFR tyrosine kinase inhibitor osimertinib. Oncogenic RAS mutants weaken or severely reduce GAP activity, resulting in persistent activation, which is the basis for oncogenic RAS signaling. Direct inhibition of RAS has proven extremely challenging and undruggable due to the picomolar affinity of GTP for its binding site, the lack of other well-defined pockets, and the extended, planar protein-protein interactions of RAS with GEFs, GAPs, and effectors. Therefore, targeting the upstream guanine nucleotide exchange factor, SOS protein, to inhibit RAS activation holds promise.

[0005] SOS has two human isotypes, SOS1 and SOS2, but most research has focused on SOS1. Human SOS1 contains 1333 amino acids (15 kDa), including an N-terminal histone-like domain, a Dbl homology (DH) domain, a pleckstrin homology (PH) domain, a helical linker (HL), a Ras exchange motif (Rem) domain, a Cdc25 domain, and a C-terminal region. PH, Rem, and Cdc25 are the components of SOS1. cat It is a component of the core catalytic domain.

[0006] Over the past few decades, the RAS family protein-SOS1 protein interaction has been increasingly recognized. Recently, research has been conducted to combine rational design and screening platforms to screen and identify low-molecular-weight inhibitors of SOS1, i.e., compounds that bind to SOS1 and inhibit protein-protein interactions with RAS family proteins. For example, WO2021105960A1 describes various fused-ring SOS1 inhibitors.

[0007] Although several small molecule inhibitors of SOS1 have been disclosed, none of the SOS1 inhibitors currently in development have been commercialized, and there remains an urgent need to develop new compounds with commercial potential and better efficacy and pharmacokinetic properties. Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide compounds having novel structures as SOS1 inhibitors, their compositions, preparation methods and use thereof for treating SOS1-mediated diseases. [Means for solving the problem]

[0009] A first aspect of the present invention provides a compound represented by the following formula (A), and a stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative thereof: [ka] During the ceremony, [ka] represents a single bond or a double bond, Y and Z are both selected from C or N, and when Y is N, Z is C, and when Y is C, Z is N; Y and Z together with the atoms connected thereto form a ring A, and ring A is selected from a 5- to 12-membered heterocyclyl group or a 5- to 12-membered heteroaryl group; R2 is one, two or three, and each occurrence independently represents hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, C 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl)2, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl)2, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted with one or more cyano groups, hydroxy groups, or halogen atoms. R 3 is hydrogen, halogen, hydroxy group, amino group, cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, wherein 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted with one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl groups, C 4~12 Cycloalkenyl group, 4- to 12-membered heterocyclyl group, C 6~12 Aryl group, 5- to 12-membered heteroaryl group, C6~12 Aryl fused C 4~12 Cycloalkyl groups, C 6~12 Aryl-fused 4- to 12-membered heterocyclyl group or C 6~12 Aryl fused C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, cyano, halogen, amino, hydroxy, oxo, nitro, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, wherein said C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally be substituted with a halogen, a hydroxy group, an amino group, -SO2-C 1~4 optionally substituted by one or more of the substituents being alkyl or oxo groups, and w is 0, 1, 2, 3, or 4; [ka] is a double bond, X is selected from C and R connected thereto 1 -OR A , -N(R D )R B or R C Selected from R 1 -OR A If so, R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D )R B If so, RB is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is hydrogen, halogen, hydroxy group, cyano group, amino group, nitro group, oxo group, formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 alkyl)2, R 1 R C If so, R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each optionally contain deuterium, a hydroxy group, a cyano group, C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; [ka] is a single bond, X is selected from N and R connected to it 1 is C 3~10 Cycloalkyl groups, C 3~10 Cycloalkenyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 3~10 Cycloalkyl groups, C 3~10 Cycloalkenyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each optionally be one or more of the same or different R a4 and / or R b4 may be replaced by Each R a4 are, if present, each independently: C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally contain one or more of the same or different R b4 and / or R c4 may be replaced by Each R b4 are, if present, each independently -OR c4 , -NR c4 R c4 , halogen, -CN, -C(O)R c4 , -C(O)OR c4 , -C(O)NR c4 R c4 , -OC(O)R c4 , -S(O)2R c4 , -S(O)NR c4 R c4 , -NHC(O)R c4 , -N(C 1~4 alkyl)C(O)R c4 , -NHC(O)OR c4 or divalent substituents =O or =NH, where =O and =NH may be the only substituents on the non-aromatic ring system; Each R c4 are, if present, each independently hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally contain one or more of the same or different R d4 and / or R e4 may be replaced by Each Rd4 are, if present, each independently -OR e4 , -NR e4 R e4 , halogen, -CN, -C(O)R e4 , -C(O)OR e4 , -C(O)NR e4 R e4 , -S(O)2R e4 , -S(O)NR e4 R e4 , -NHC(O)R e4 , -N(C 1~4 alkyl)C(O)R e4 or the divalent substituent =O, where =O may be the only substituent on the non-aromatic ring system; Each R e4 are, if present, each independently hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted with one or more hydrogen atoms, cyano groups, hydroxy groups, or halogen atoms. Here, Z and Y are included in the number of atoms or atoms of ring A.

[0010] Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N, or S, and the number of heteroatoms is 1, 2, 3, or 4.

[0011] Preferably, the present invention provides a compound having a structure represented by formula (A'), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof, [ka] Each substituent in formula (A') is defined as described in formula (A).

[0012] The present invention also provides a compound represented by the following formula (I), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs or solvates thereof: [ka] During the ceremony, [ka] represents a single bond or a double bond, Y and Z are both selected from C or N, and when Y is N, Z is C, and when Y is C, Z is N; Y and Z together with the atoms connected thereto form a ring A, and ring A is selected from a 5- to 12-membered heterocyclyl group or a 5- to 12-membered heteroaryl group; R 2 is one, two or three, and each occurrence independently represents hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, C 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl)2, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl)2, C 2~6 Alkenyl group, C 2~6Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted with one or more cyano groups, hydroxy groups, or halogen atoms. R 3 is hydrogen, halogen, hydroxy group, amino group, cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, wherein 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted with one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl groups, C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 5~12 Heteroaryl groups, C 6~12 Aryl fused C 4~12 Cycloalkyl groups, C 6~12 Aryl fused C 4~12 Heterocyclyl group or C 6~12 Aryl fused C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, cyano, halogen, amino, hydroxy, oxo, nitro, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, wherein said C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally be substituted with a halogen, a hydroxy group, an amino group, -SO2-C 1~4 optionally substituted by one or more of the substituents being alkyl or oxo groups, and w is 0, 1, 2, 3, or 4; [ka] is a double bond, X is selected from C and R connected thereto 1 -OR A , -N(R D )R B or R C Selected from R 1 -OR A If so, R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different Ra1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D )R B If so, R B is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is hydrogen, halogen, hydroxy group, cyano group, amino group, nitro group, oxo group, formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 alkyl)2, R 1 R C If so, R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R c1may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each optionally contain a hydroxy group, C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; [ka] is a single bond, X is selected from N and R connected to it 1 is C 3~10 Cycloalkyl groups, C3~10 Cycloalkenyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 3~10 Cycloalkyl groups, C 3~10 Cycloalkenyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally contain one or more of the same or different R a4 and / or R b4 may be replaced by Each R a4 are, if present, each independently: C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally contain one or more of the same or different R b4 and / or R c4 may be replaced by Each R b4 are, if present, each independently -OR c4 , -NR c4 R c4 , halogen, -CN, -C(O)R c4 , -C(O)OR c4 , -C(O)NR c4 R c4 , -OC(O)R c4 , -S(O)2R c4 , -S(O)NR c4 R c4 , -NHC(O)R c4 , -N(C 1~4 alkyl)C(O)R c4 , -NHC(O)OR c4or divalent substituents =O or =NH, where =O and =NH may be the only substituents on the non-aromatic ring system; Each R c4 are, if present, each independently hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally contain one or more of the same or different R d4 and / or R e4 may be replaced by Each R d4 are, if present, each independently -OR e4 , -NR e4 R e4 , halogen, -CN, -C(O)R e4 , -C(O)OR e4 , -C(O)NR e4 R e4 , -S(O)2R e4 , -S(O)NR e4 R e4 , -NHC(O)R e4 , -N(C 1~4 alkyl)C(O)R e4 or the divalent substituent =O, where =O may be the only substituent on the non-aromatic ring system; Each R e4 are, if present, each independently hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted with one or more hydrogen atoms, cyano groups, hydroxy groups, or halogen atoms. Here, Z and Y are included in the number of atoms or atoms of ring A.

[0013] Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N, or S, and the number of heteroatoms is 1, 2, 3, or 4.

[0014] Preferably, the present invention provides a compound having the structure of formula (II), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, or solvates thereof: [ka] Each substituent in formula (II) is defined as described in formula (I).

[0015] Preferably, the present invention provides a compound having the structure of formula (III), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, or solvates thereof: [ka] Each substituent in formula (III) is defined as described in formula (I).

[0016] Preferably, the present invention provides a compound having the structure of formula (IV), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, or solvates thereof: [ka] Each substituent in formula (IV) is defined as described in formula (I).

[0017] In one preferred embodiment of the present invention, [ka] is a double bond, and X is selected from C and R connected thereto. 1 -OR A is.

[0018] Preferably, R A is C 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 alkyl)2.

[0019] More preferably, R A is C 3~6 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 6-membered heterocyclyl group, or a 5- to 6-membered heteroaryl group, wherein 3~6 Cycloalkyl groups, C 6~10The aryl group, the 3- to 6-membered heterocyclyl group, and the 5- to 6-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0020] More preferably, R A is selected from a 5- to 6-membered heterocyclyl group or a 5- to 6-membered heteroaryl group, wherein the 5- to 6-membered heterocyclyl group and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group or -COC 1~4 It is selected from alkyl groups.

[0021] More preferably, R A is selected from 5- to 6-membered heterocyclyl groups, wherein the 5- to 6-membered heterocyclyl groups are optionally selected from 1 to 2 identical or different R a1 may be replaced by Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0022] More preferably, R A is selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein the 5- to 6-membered monocyclic heterocyclyl groups may optionally be selected from 1 to 2 identical or different R a1wherein the 5- to 6-membered monocyclic heterocyclyl group is optionally substituted by one heteroatom, each heteroatom being independently selected from O, N, or S; Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0023] More preferably, R A is selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally contain one to two identical or different R a1 may be replaced by Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0024] More preferably, R A is the following functional group: [ka] Selected from.

[0025] In one preferred embodiment of the present invention, [ka] is a double bond, and X is selected from C and R connected thereto. 1 is -N(R D )R B is.

[0026] Preferably, R B is C 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0027] More preferably, R B is C 1~6 alkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 The alkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0028] More preferably, R B is C 1~6 alkyl group or 5- to 6-membered monocyclic heterocyclyl group, wherein 1~6 The alkyl group and the 5- to 6-membered monocyclic heterocyclyl group each optionally have one to two identical or different R b1wherein the 5- to 6-membered monocyclic heterocyclyl group is optionally substituted by one heteroatom, each heteroatom being independently selected from O, N, or S; Each R b1 When present, each independently represents a halogen, an oxo group, a formyl group, or C 1~4 Alkyl group, -OC 1~4 Alkyl group or -COC 1~4 It is selected from alkyl groups.

[0029] More preferably, R B is selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group each optionally have one to two identical or different R b1 may be replaced by Each R b1 When present, each is independently selected from oxo, formyl, acetyl, methyl, ethyl, methoxy, or ethoxy.

[0030] More preferably, R B is the following functional group: [ka] Selected from.

[0031] Preferably, R D is hydrogen, C 1~6 Alkyl group or -OC 1~6 alkyl groups, more preferably R D is hydrogen or C 1~3 alkyl groups, more preferably R D is selected from hydrogen or a methyl group, and most preferably RD is selected from hydrogen.

[0032] In one preferred embodiment of the present invention, [ka] is a double bond, and X is selected from C and R connected thereto. 1 is R C is.

[0033] Preferably, R C is C 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 cycloalkyl group or 3- to 10-membered heterocyclyl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 The cycloalkyl group and the 3- to 10-membered heterocyclyl group may each optionally be substituted with a hydroxy group, a C 1~3 Alkyl group, C 1~3 It may be substituted with one or more substituents selected from an alkoxy group or a halogen.

[0034] More preferably, R C is C 1~6 Alkyl group, C 3~10 a cycloalkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 3~10 The cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH2CON(C 1~4 alkyl)2, -CH2CONHC 1~4 alkyl group or 3- to 6-membered heterocyclyl group, wherein 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH2CON(C 1~4 alkyl)2, -CH2CONHC 1~4The alkyl group and the 3- to 6-membered heterocyclyl group may both be optionally substituted with one or more substituents selected from a hydroxy group, a methyl group, a methoxy group, or a halogen.

[0035] More preferably, R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH2CON(C 1~4 alkyl) 2- or 3- to 6-membered heterocyclyl groups, wherein the C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH2CON(C 1~4 The alkyl)2 and 3- to 6-membered heterocyclyl groups may each be optionally substituted with one or more substituents selected from a hydroxy group, a methyl group, a methoxy group, or a halogen.

[0036] More preferably, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, or a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally have 1 to 3 identical or different R c1 may be replaced by Each R c1are, when present, each independently selected from halogen, hydroxy, cyano, amino, oxo, formyl, acetyl, propionyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, -CHCON(CH) or a 6-membered heterocyclyl group, wherein the acetyl, propionyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, -CHCON(CH) and 6-membered heterocyclyl groups are all optionally substituted with one or more substituents selected from hydroxy, methyl, methoxy or halogen.

[0037] More preferably, R C is selected from a 6-membered monocyclic heterocyclyl group, a 4 / 6 spiroheterocyclyl group, a 4 / 4 spiroheterocyclyl group, a 7-membered bridged heterocyclyl group, and a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4 / 6 spiroheterocyclyl group, the 4 / 4 spiroheterocyclyl group, the 7-membered bridged heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally contain 1 to 3 of the same or different R c1 may be replaced by Each R c1 When present, each independently is selected from halogen, hydroxy, cyano, amino, oxo, formyl, acetyl, -COCHCH, -COCHOH, hydroxymethyl, hydroxyethyl, -CHOCH, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, -CHCON(CH) or a 6-membered heterocyclyl group.

[0038] More preferably, R C teeth, [ka] wherein R C Each of these may contain one or two identical or different R c1 may be replaced by Each R c1When present, each is independently selected from F, Cl, Br, hydroxy, cyano, amino, oxo, acetyl, -COCH2CH3, -COCH2OH, hydroxymethyl, hydroxyethyl, -CH2OCH3, methoxy, methyl, ethyl, isopropyl, -CH2CON(CH3)2, and morpholinyl.

[0039] More preferably, optionally R c1 R may be replaced by C is the following functional group: [ka] Selected from.

[0040] In one preferred embodiment of the present invention, ring A is selected from a 5- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the heteroatoms in the 5- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group are each independently selected from O or N, and the number of heteroatoms is 1 to 4.

[0041] More preferably, ring A is selected from a 5-membered monocyclic heterocyclyl group, a 6-membered monocyclic heterocyclyl group, a 5-membered monocyclic heteroaryl group, a 6-membered monocyclic heteroaryl group, a 5 / 5-membered fused heterocyclyl group, a 5 / 4-membered fused heterocyclyl group, a 5 / 6-membered fused heterocyclyl group, a 6 / 5-membered fused heterocyclyl group, a 6 / 4-membered fused heterocyclyl group, a 6 / 6-membered fused heterocyclyl group, a 5 / 3-membered spiroheterocyclyl group, a 5 / 5-membered spiroheterocyclyl group, a 5 / 4-membered spiroheterocyclyl group, a 5 / 6-membered spiroheterocyclyl group, a 6 / 3-membered spiroheterocyclyl group, a 6 / 5-membered spiroheterocyclyl group, a 6 / 4-membered spiroheterocyclyl group, or a 6 / 6-membered spiroheterocyclyl group, wherein said 5-membered monocyclic heterocyclyl group The heteroatoms in the acryl group, 6-membered monocyclic heterocyclyl group, 5-membered monocyclic heteroaryl group, 6-membered monocyclic heteroaryl group, 5 / 5-membered fused heterocyclyl group, 5 / 4-membered fused heterocyclyl group, 5 / 6-membered fused heterocyclyl group, 6 / 5-membered fused heterocyclyl group, 6 / 4-membered fused heterocyclyl group, 6 / 6-membered fused heterocyclyl group, 5 / 3-membered spiroheterocyclyl group, 5 / 5-membered spiroheterocyclyl group, 5 / 4-membered spiroheterocyclyl group, 5 / 6-membered spiroheterocyclyl group, 6 / 3-membered spiroheterocyclyl group, 6 / 5-membered spiroheterocyclyl group, 6 / 4-membered spiroheterocyclyl group, and 6 / 6-membered spiroheterocyclyl group are each independently selected from N, and the number of heteroatoms is 1 to 4.

[0042] More preferably, ring A is selected from a 5-membered monocyclic heterocyclyl group, a 6-membered monocyclic heterocyclyl group, a 5-membered monocyclic heteroaryl group, a 6-membered monocyclic heteroaryl group, a 5 / 5-membered fused heterocyclyl group, a 5 / 6-membered fused heterocyclyl group, or a 5 / 3-membered spiroheterocyclyl group, wherein the heteroatoms in the 5-membered monocyclic heterocyclyl group, 6-membered monocyclic heterocyclyl group, 5-membered monocyclic heteroaryl group, 6-membered monocyclic heteroaryl group, 5 / 5-membered fused heterocyclyl group, 5 / 6-membered fused heterocyclyl group, and 5 / 3-membered spiroheterocyclyl group are each independently selected from N, and the number of heteroatoms is 1 to 3.

[0043] More preferably, ring A is selected from a 5-membered monocyclic heterocyclyl group or a 5-membered monocyclic heteroaryl group, and the heteroatom in the 5-membered monocyclic heterocyclyl group and the 5-membered monocyclic heteroaryl group is selected from N, and the number of heteroatoms is 1 to 3.

[0044] More preferably, ring A contains the following functional group: [ka] Selected from.

[0045] More preferably, ring A contains the following functional group: [ka] Selected from.

[0046] In one preferred embodiment of the present invention, R 2 is one, two or three, and each occurrence independently represents hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, C 1~3 Alkyl group, C 1~3 Alkoxy group, -C 1~3 Alkyl-NH(C 1~3 alkyl) or -C 1~3 Alkyl-N(C 1~3 alkyl)2, wherein said C 1~3 Alkyl group, C 1~3 Alkoxy group, -C 1~3 Alkyl-NH(C 1~3 alkyl) and -C 1~3 Alkyl-N(C 1~3 alkyl)2 may each be optionally substituted with one or more hydroxy groups or halogens; More preferably, R 2 is one, two or three and, when it occurs, is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, methoxy, methyl, ethyl, n-propyl or isopropyl; More preferably, R 2 is one or two, and each occurrence is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, methoxy, or methyl; More preferably, R 2 is one or two, and when it occurs, each is independently selected from hydrogen or a methyl group.

[0047] In one preferred embodiment of the present invention, R 3 is hydrogen, halogen, hydroxy group, amino group, cyano group, C 1~4 Alkyl group, C 1~4 Alkoxy group or C 3~6 cycloalkyl groups, wherein said C 1~4 Alkyl group, C 1~4 Alkoxy groups and C 3~6 Any cycloalkyl group may be optionally substituted with one or more hydroxy groups or halogens; More preferably, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a methoxy group; More preferably, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and a cyclopropyl group; More preferably, R 3 is selected from hydrogen, F, Cl, Br, an amino group, a methyl group, an ethyl group, or a cyclopropyl group.

[0048] In one preferred embodiment of the present invention, ring B is C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 6~8 Aryl fused C 4~6 Cycloalkyl groups, C 6~8 Aryl fused C 4~6 Heterocyclyl group or C5~12 Heteroaryl groups are selected from the group consisting of:

[0049] More preferably, ring B is C 6~10 Aryl group or C 5~10 Heteroaryl groups are selected from the group consisting of:

[0050] More preferably, ring B is selected from a phenyl group or a pyridinyl group.

[0051] In one preferred embodiment of the present invention, each R 4 When present, each independently represents a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, or C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl groups, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, wherein said C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl groups, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally be substituted with a halogen, a hydroxy group, an amino group, -SO2-C 1~4 It may be substituted with one or more of the substituents being alkyl or oxo groups, and w is 0, 1, 2 or 3.

[0052] More preferably, each R 4 are each independently hydrogen, cyano group, halogen, amino group, nitro group, C 1~4 Alkyl group, C 1~4 haloalkyl group or C 1~4 hydroxyalkyl groups, wherein the C 1~4 Alkyl group, C 1~4 Haloalkyl groups and C 1~4 Any hydroxyalkyl group may be optionally substituted with one or more of the following substituents: halogen, hydroxy, or amino; and w is 1, 2, or 3.

[0053] More preferably, each R 4 are each independently selected from hydrogen, cyano, halogen, amino, nitro, methyl, ethyl, n-propyl, or isopropyl, each of which may optionally be substituted with one or more halogen or hydroxy substituents; and w is 1, 2, or 3.

[0054] More preferably, each R 4 are each independently selected from hydrogen, halogen, amino, methyl, ethyl, or isopropyl, wherein any of the methyl, ethyl, and isopropyl groups may be optionally substituted with one or more substituents which are halogen or hydroxy groups; and w is 1, 2, or 3.

[0055] More preferably, each R 4 are each independently selected from hydrogen, halogen, an amino group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, —CF2CH2OH, —C(CH3)2OH, or —CF2CH3; and w is 1, 2, or 3.

[0056] The present invention also provides a compound having the structure represented by formula (B), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof, [ka] In the formula, R 1 -OR A , -N(R D )R B or R C Selected from R 1 -OR A If so, R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D )R B If so, R B is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is hydrogen, halogen, hydroxy group, cyano group, amino group, nitro group, oxo group, formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 alkyl)2, R 1 R C If so, R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each optionally contain deuterium, a hydroxy group, a cyano group, C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; R 2 is one or two, and when it occurs, each independently represents hydrogen, halogen, hydroxyl group, cyano group, amino group, nitro group, formyl group, oxo group, C 1~6 Alkyl group, C 1~6 Alkoxy group, haloC 1~6 Alkyl or halo C 1~6 selected from alkoxy groups, R 3 is hydrogen, halogen, hydroxy group, amino group, cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, wherein 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted with one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl groups, C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 5~12 Heteroaryl groups, C 6~12 Aryl fused C 4~12 Cycloalkyl groups, C 6~12 Aryl fused C 4~12 Heterocyclyl group or C 6~12 Aryl fused C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, cyano, halogen, amino, hydroxy, oxo, nitro, C 1~6 Alkyl group, C 2~6 Alkenyl group, C2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, wherein said C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl)(C 1~6 alkyl), C 3~6 Cycloalkyl groups, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally be substituted with a halogen, a hydroxy group, an amino group, -SO2-C 1~4 optionally substituted by one or more of the substituents being alkyl or oxo groups, and w is 0, 1, 2, 3, or 4; Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N, or S, and the number of heteroatoms is 1, 2, 3, or 4.

[0057] In one preferred embodiment of the present invention, R 1 -OR A and R A is C 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 alkyl)2.

[0058] More preferably, R A is C 3~6 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 6-membered heterocyclyl group, or a 5- to 6-membered heteroaryl group, wherein 3~6 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 6-membered heterocyclyl group, and the 5- to 6-membered heteroaryl group each optionally contain 1 to 3 of the same or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0059] More preferably, R Ais selected from a 5- to 6-membered heterocyclyl group or a 5- to 6-membered heteroaryl group, wherein the 5- to 6-membered heterocyclyl group and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be replaced by Each R a1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group or -COC 1~4 It is selected from alkyl groups.

[0060] More preferably, R A is selected from 5- to 6-membered heterocyclyl groups, wherein the 5- to 6-membered heterocyclyl groups are optionally selected from 1 to 2 identical or different R a1 may be replaced by Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0061] More preferably, R A is selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein the 5- to 6-membered monocyclic heterocyclyl groups may optionally be selected from 1 to 2 identical or different R a1 wherein the 5- to 6-membered monocyclic heterocyclyl group is optionally substituted by one heteroatom, each heteroatom being independently selected from O, N, or S; Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0062] More preferably, R Ais selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally contain one to two identical or different R a1 may be replaced by Each R a1 When present, each independently is selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy.

[0063] More preferably, R A is the following functional group: [ka] Selected from.

[0064] In one preferred embodiment of the present invention, R 1 is -N(R D )R B and R B is C 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 Alkyl group, C 3~10 Cycloalkyl groups, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 3 of the same or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0065] More preferably, R B is C 1~6 alkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 1~6 The alkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be replaced by Each R b1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0066] More preferably, R B is C 1~6 alkyl group or 5- to 6-membered monocyclic heterocyclyl group, wherein 1~6 The alkyl group and the 5- to 6-membered monocyclic heterocyclyl group each optionally have one to two identical or different R b1 wherein the 5- to 6-membered monocyclic heterocyclyl group is optionally substituted with one heteroatom, each heteroatom being independently selected from O, N, or S; Each R b1 When present, each independently represents a halogen, an oxo group, a formyl group, or C 1~4 Alkyl group, -OC 1~4 Alkyl group or -COC 1~4 It is selected from alkyl groups.

[0067] More preferably, R Bis selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group each optionally have one to two identical or different R b1 may be replaced by Each R b1 When present, each is independently selected from oxo, formyl, acetyl, methyl, ethyl, methoxy, or ethoxy.

[0068] More preferably, R B is the following functional group: [ka] Selected from.

[0069] R D is hydrogen, C 1~6 Alkyl group or -OC 1~6 alkyl groups, more preferably R D is hydrogen or C 1~3 alkyl groups, more preferably R D is selected from hydrogen or a methyl group, and most preferably R D is selected from hydrogen.

[0070] In one preferred embodiment of the present invention, R 1 is R C and R C is C 3~10 Cycloalkyl groups, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 3~10 Cycloalkyl groups, C 6~10The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally contain 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 cycloalkyl group or 3- to 10-membered heterocyclyl group, wherein 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~6 Alkyl group, -CH2CON(C 1~6 alkyl)2, -CH2CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl)2, C 3~10 The cycloalkyl group and the 3- to 10-membered heterocyclyl group may each optionally contain deuterium, a hydroxy group, a cyano group, a C 1~3 Alkyl group, C 1~3 It may be substituted with one or more substituents selected from an alkoxy group or a halogen.

[0071] More preferably, R C is C 3~10 a cycloalkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, wherein 3~10The cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~4 Alkyl group, -CH2CON(C 1~4 alkyl)2, -CH2CONHC 1~4 Alkyl group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, wherein 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2COC 1~4 Alkyl group, -CH2CON(C 1~4 alkyl)2, -CH2CONHC 1~4 Alkyl group, C 3~6 The cycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally contain deuterium, a hydroxy group, a cyano group, a C 1~3 Alkyl group, C 1~3 It may be substituted with one or more substituents selected from an alkoxy group or a halogen.

[0072] More preferably, R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 of the same or different R c1 may be replaced by Each R c1When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, an oxo group, a formyl group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2CON(C 1~4 alkyl) 2- or 3- to 6-membered heterocyclyl groups, wherein the C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2CON(C 1~4 The alkyl) 2 and 3- to 6-membered heterocyclyl groups may each be optionally substituted with one or more substituents selected from deuterium, hydroxy, cyano, methyl, methoxy, or halogen.

[0073] More preferably, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, an 8- to 10-membered fused heterocyclyl group, or a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, the 8- to 10-membered fused heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally comprises 1 to 4 of the same or different R c1 may be replaced by Each R c1are, when present, each independently selected from halogen, hydroxy, cyano, amino, oxo, formyl, acetyl, propionyl, methanesulfonyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, —CHCON(CH), —CO-cyclopropyl, —CO-cyclobutyl, 4-membered, 5-membered or 6-membered heterocyclyl, wherein the acetyl, propionyl, methanesulfonyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, —CHCON(CH), —CO-cyclopropyl, —CO-cyclobutyl, 4-membered, 5-membered or 6-membered heterocyclyl groups are all optionally substituted by one or more substituents selected from deuterium, hydroxy, cyano, methyl, methoxy or halogen.

[0074] More preferably, R C is selected from a 6-membered monocyclic heterocyclyl group, a 4-membered / 6-membered spiroheterocyclyl group, a 4-membered / 4-membered spiroheterocyclyl group, a 6-membered / 5-membered fused heterocyclyl group, a 7-membered bridged heterocyclyl group, or a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4-membered / 6-membered spiroheterocyclyl group, the 4-membered / 4-membered spiroheterocyclyl group, the 6-membered / 4-membered fused heterocyclyl group, the 7-membered bridged heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally have 1 to 4 of the same or different R c1 may be replaced by Each R c1are, when present, each independently selected from halogen, hydroxy, cyano, amino, oxo, formyl, acetyl, propionyl, methanesulfonyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, -CHCON(CH), -CO-cyclopropyl, 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl, wherein the acetyl, propionyl, methanesulfonyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, -CHCON(CH), -CO-cyclopropyl, 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl groups are all optionally substituted by one or more substituents selected from deuterium, hydroxy, cyano, methyl, methoxy, and halogen.

[0075] More preferably, R C teeth, [ka] wherein R C Each of the groups may optionally contain 1 to 4 identical or different R c1 may be replaced by Each R c1 When present, each independently represents F, Cl, Br, hydroxy, cyano, amino, oxo, methanesulfonyl, acetyl, -COCH2CH3, -COCH2OH, -COCH2CN, -CH(OH)(CH3)2, hydroxymethyl, hydroxyethyl, -CH2OCH3, -CH2CH2OCH3, methoxy, methyl, CD3, ethyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, [ka] , —CH2CON(CH3)2 or a morpholinyl group.

[0076] More preferably, optionally Rc1 may be replaced by R C is the following functional group: [ka] Selected from.

[0077] In one preferred embodiment of the present invention, R 2 is one or two, and when it occurs, each is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, methoxy, methyl, ethyl, n-propyl, and isopropyl.

[0078] More preferably, R 2 is one or two, and when it occurs, each is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, methoxy, or methyl.

[0079] More preferably, R 2 is one or two, and when it occurs, each is independently selected from hydrogen or a methyl group.

[0080] More preferably, R 2 is hydrogen.

[0081] In one preferred embodiment of the present invention, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a methoxy group.

[0082] More preferably, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and a cyclopropyl group.

[0083] More preferably, R 3is selected from hydrogen, F, Cl, Br, an amino group, a methyl group, an ethyl group, or a cyclopropyl group.

[0084] In one preferred embodiment of the present invention, ring B is C 4~12 Cycloalkenyl group, 4- to 12-membered heterocyclyl group, C 6~12 Aryl group, C 6~8 Aryl fused C 4~6 Cycloalkyl groups, C 6~8 It is selected from an aryl-fused 4- to 6-membered heterocyclyl group and a 5- to 12-membered heteroaryl group.

[0085] More preferably, ring B is C 6~10 an aryl group, a 5- to 10-membered heteroaryl group, or C 6~8 It is selected from aryl-fused 4- to 6-membered heterocyclyl groups.

[0086] More preferably, ring B is selected from a phenyl group, a pyridinyl group, or a benzotetrahydrofuryl group.

[0087] In one preferred embodiment of the present invention, each R 4 When present, each independently represents a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, or C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl groups, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, wherein said C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl groups, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group may each optionally be substituted with a halogen, a hydroxy group, an amino group, -SO2-C 1~4 It may be substituted with one or more of the substituents being alkyl or oxo groups, and w is 0, 1, 2 or 3.

[0088] More preferably, each R 4 are each independently hydrogen, cyano group, halogen, amino group, nitro group, C 1~4 Alkyl group, C 1~4 haloalkyl group or C 1~4 hydroxyalkyl groups, wherein the C 1~4 Alkyl group, C 1~4 Haloalkyl groups and C 1~4 Any hydroxyalkyl group may be optionally substituted with one or more of the following substituents: halogen, hydroxy, or amino; and w is 1, 2, or 3.

[0089] More preferably, each R 4 are each independently selected from hydrogen, cyano, halogen, amino, nitro, methyl, ethyl, n-propyl, or isopropyl, each of which may optionally be substituted with one or more halogen or hydroxy substituents; and w is 1, 2, or 3.

[0090] More preferably, each R 4 are each independently selected from hydrogen, halogen, amino, cyano, methyl, ethyl, or isopropyl, wherein the methyl, ethyl, and isopropyl groups are all optionally substituted with one or more halogen or hydroxy substituents; and w is 1, 2, or 3.

[0091] More preferably, each R 4 are each independently selected from hydrogen, fluorine, an amino group, a cyano group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, —CF2CH2OH, —C(CH3)2OH, —CF2CH3, or —CH2CHF2; and w is 1, 2, or 3.

[0092] The present invention provides a compound having the structure represented by formula (C), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof, [ka] Each substituent in formula (C) is defined as described in formula (B).

[0093] The present invention also provides a compound having the structure represented by formula (D), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof: [ka] In the formula, R 1 , R 4 , w is defined as described in Formula (A), Formula (A'), Formula (I), Formula (II), Formula (III), Formula (IV), Formula (B) or Formula (C).

[0094] Preferably, each R 4 each independently, when present, represents a cyano group, a halogen, an amino group, or C 1~6 Alkyl group or C 1~6 haloalkyl groups, wherein said C 1~6 Alkyl groups and C 1~6 any haloalkyl group may be optionally substituted with one or more hydroxy groups; w is 1 or 2; R 1 -OR A , -N(R D )R B or R C Selected from R 1 -OR A If so, R A is selected from a 3- to 10-membered heterocyclyl group, wherein the 3- to 10-membered heterocyclyl group is optionally selected from 1 to 3 of the same or different R a1 may be replaced by Each R a1 are, if present, each independently: C 1~6 Alkyl group or -COC 1~6 alkyl groups, R 1 -N(R D )RB If so, R B is C 1~6 alkyl group or 3- to 10-membered heterocyclyl group, wherein 1~6 The alkyl group and the 3- to 10-membered heterocyclyl group each optionally have 1 to 3 identical or different R b1 may be replaced by Each R b1 are, if present, each independently -OC 1~6 selected from alkyl groups, R D is selected from hydrogen, R 1 R C If so, R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a methanesulfonyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2CON(C 1~6 alkyl) 2- or 3- to 10-membered heterocyclyl groups, wherein the C 1~6 Alkyl group, -OC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2CON(C 1~6 The 2- and 3- to 10-membered alkyl groups may each optionally be substituted with deuterium, a hydroxy group, a cyano group, or a C 1~3 It may be substituted with one or more substituents selected from an alkoxy group or a halogen.

[0095] Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N, or S, and the number of heteroatoms is 1, 2, 3, or 4.

[0096] In one preferred embodiment of the present invention, R 1 -OR A and R A is selected from a 3- to 6-membered heterocyclyl group, wherein the 3- to 6-membered heterocyclyl group is optionally selected from 1 to 3 of the same or different R a1 may be replaced by Each R a1 are, if present, each independently: C 1~6 Alkyl group or -COC 1~6 It is selected from alkyl groups.

[0097] More preferably, R A is selected from 5- to 6-membered heterocyclyl groups, wherein the 5- to 6-membered heterocyclyl groups are optionally selected from 1 to 2 identical or different R a1 may be replaced by Each R a1 When present, each is independently selected from an acetyl group, a methyl group, an ethyl group, an n-propyl group, or an isopropyl group.

[0098] More preferably, R A is selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein the 5- to 6-membered monocyclic heterocyclyl groups may optionally be selected from 1 to 2 identical or different R a1 wherein the 5- to 6-membered monocyclic heterocyclyl group is optionally substituted by one heteroatom, each heteroatom being independently selected from O, N, or S; Each R a1 When present, each is independently selected from an acetyl group, a methyl group, or an ethyl group.

[0099] More preferably, R Ais selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally contain one to two identical or different R a1 may be replaced by Each R a1 When present, each is independently selected from an acetyl group, a methyl group, or an ethyl group.

[0100] More preferably, R A is the following functional group: [ka] Selected from.

[0101] In one preferred embodiment of the present invention, R 1 is -N(R D )R B and R B is C 1~6 alkyl group or 3- to 6-membered monocyclic heterocyclyl group, wherein 1~6 The alkyl group and the 3- to 6-membered monocyclic heterocyclyl group each optionally have one to two identical or different R b1 each heteroatom in the 3- to 6-membered monocyclic heterocyclyl group is independently selected from O, N, or S, and the number of heteroatoms is 1; Each R b1 are, if present, each independently -OC 1~4 It is selected from alkyl groups.

[0102] More preferably, R Bis selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group each optionally have one to two identical or different R b1 may be replaced by Each R b1 When present, each is independently selected from a methoxy group or an ethoxy group.

[0103] More preferably, R B is the following functional group: [ka] Selected from.

[0104] In one preferred embodiment of the present invention, R 1 is R C and R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 of the same or different R c1 may be replaced by Each R c1 When present, each independently represents a halogen, a hydroxy group, a cyano group, an amino group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl groups, -CH2CON(C 1~4 alkyl) 2- or 3- to 6-membered heterocyclyl groups, wherein the C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6Cycloalkyl groups, -CH2CON(C 1~4 The alkyl)2 and 3- to 6-membered heterocyclyl groups may each be optionally substituted with one or more substituents selected from deuterium, hydroxy, cyano, methoxy, or halogen.

[0105] More preferably, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, an 8- to 10-membered fused heterocyclyl group, or a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, the 8- to 10-membered fused heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally comprises 1 to 4 of the same or different R c1 may be replaced by Each R c1 are, when present, each independently selected from halogen, hydroxy, cyano, amino, methanesulfonyl, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, acetyl, propionyl, -CO-cyclopropyl, -CO-cyclobutyl, -CHCON(CH), 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl, wherein the methanesulfonyl, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, acetyl, propionyl, -CO-cyclopropyl, -CO-cyclobutyl, -CHCON(CH), 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl groups are all optionally substituted by one or more substituents selected from deuterium, hydroxy, cyano, methoxy, and halogen.

[0106] More preferably, R Cis selected from a 6-membered monocyclic heterocyclyl group, a 4-membered / 6-membered spiroheterocyclyl group, a 4-membered / 4-membered spiroheterocyclyl group, a 7-membered bridged heterocyclyl group, a 6-membered / 5-membered fused heterocyclyl group, or a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4-membered / 6-membered spiroheterocyclyl group, the 4-membered / 4-membered spiroheterocyclyl group, the 7-membered bridged heterocyclyl group, the 6-membered / 4-membered fused heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally comprises 1 to 4 of the same or different R c1 may be replaced by Each R c1 are, when present, each independently selected from halogen, hydroxy, cyano, amino, methanesulfonyl, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, acetyl, propionyl, -CO-cyclopropyl, -CHCON(CH), 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl, wherein the methanesulfonyl, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, acetyl, propionyl, -CO-cyclopropyl, 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl groups are all optionally substituted by one or more substituents selected from deuterium, hydroxy, cyano, methoxy, and halogen.

[0107] More preferably, R C teeth, [ka] wherein R C Each of the groups may optionally contain 1 to 4 identical or different R c1 may be replaced by Each R c1are, when present, each independently F, Cl, Br, a hydroxy group, a cyano group, an amino group, a methanesulfonyl group, a methyl group, an ethyl group, an isopropyl group, CD3, a hydroxymethyl group, a hydroxyethyl group (e.g., a 2-hydroxyethyl group), -CH(OH)(CH3)2, -CHOCH3, -CHCHOCH3, a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoroethyl group (e.g., a 2-fluoroethyl group), a difluoroethyl group (e.g., a 2,2-difluoroethyl group), a trifluoroethyl group (e.g., a 2,2,2-trifluoroethyl group), a methoxy group, an acetyl group, -COCHCH3, -COCHOH, -COCHCN, [ka] , -CH2CON(CH3)2, oxetanyl groups (e.g., [ka] ) or a morpholinyl group (e.g., morpholin-4-yl).

[0108] More preferably, optionally R c1 R may be replaced by C is the following functional group: [ka] Selected from.

[0109] In one preferred embodiment of the present invention, each R 4 each independently, when present, represents a cyano group, a halogen, an amino group, or C 1~4 Alkyl group or C 1~4 haloalkyl groups, wherein said C 1~4 Alkyl groups and C 1~4 Any haloalkyl group may be optionally substituted with one or more hydroxy groups; and w is 1 or 2.

[0110] More preferably, each R 4are each independently selected from a cyano group, fluorine, an amino group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, —CF2CH2OH, —CF2C(CH3)2OH, —CF2CH3, or —CH2CHF2; and w is 1 or 2.

[0111] The present invention provides a compound having a structure represented by formula (E), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof, [ka] Each substituent in formula (E) is defined as described in formula (D).

[0112] The present invention also provides a compound having a structure represented by formula (F) or formula (F'), and a stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate, or isotopic derivative thereof, [ka] In the formula, R c1 , R 4 , w is defined as described in formula (D) or formula (E), v is 0 or 1, and when v is 1, R c1 is preferably linked to the N atom.

[0113] Preferably, R c1 is a methyl group, an ethyl group, an isopropyl group, CD3, a hydroxymethyl group, a hydroxyethyl group (e.g., a 2-hydroxyethyl group), a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoroethyl group (e.g., a 2-fluoroethyl group), a difluoroethyl group (e.g., a 2,2-difluoroethyl group), a trifluoroethyl group (e.g., a 2,2,2-trifluoroethyl group), -CH2CON(CH3)2, or an oxetanyl group (e.g., [ka] ) are selected.

[0114] More preferably, [ka] is the following functional group: [ka] Selected from.

[0115] The present invention provides a compound having a structure represented by formula (G) or formula (G'), and a stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate, or isotopic derivative thereof, [ka] In the formula, R c1 , R 4 , w is defined as described in formula (D) or formula (E), v is 0 or 1, and when v is 1, R c1 is preferably linked to the N atom.

[0116] Preferably, R c1 is selected from a methyl group, an ethyl group, an isopropyl group, a hydroxymethyl group, a hydroxyethyl group (e.g., a 2-hydroxyethyl group), —CHOCH, —CHCHOCH, a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoroethyl group (e.g., a 2-fluoroethyl group), a difluoroethyl group (e.g., a 2,2-difluoroethyl group), a trifluoroethyl group (e.g., a 2,2,2-trifluoroethyl group), or —CHCON(CH).

[0117] More preferably, [ka] is the following functional group: [ka] Selected from.

[0118] Preferably, the present invention provides compounds having the following structure: and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof: [ka] [ka] [ka] [ka] [ka]

[0119] Preferably, the present invention provides compounds having the following structure: and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof: [ka] [ka] [ka] [ka] [ka] [ka]

[0120] The object of the present invention also includes providing the preparation of intermediates of the compounds of the present invention, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, said intermediates being as shown in formula (V): [ka] In the formula, R 2 , R 3 , rings A, X, Y, and Z are defined as described in formula (A), formula (I), or formula (II); R 5 is selected from halogen, a hydroxy group, an -O-methanesulfonyl group, an -Op-toluenesulfonyl group, or an -O-trifluoromethanesulfonyl group, and is preferably a chlorine atom or a hydroxy group.

[0121] R 6 is selected from halogens and is preferably bromine or iodine.

[0122] The object of the present invention also includes providing the preparation of intermediates of the compounds of the present invention, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, said intermediates being as shown in formula (VI): [ka] In the formula, R 2 , R 3 , R 4 , w, ring A, X, Y, and Z are defined as described in formula (A) or formula (I), R 6 is selected from halogens and is preferably bromine or iodine.

[0123] Additionally, the compounds of the present invention, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof, have the structure of formula (VII): [ka] In the formula, R 2 , R 3 , R 4 , w, ring A, X, Y, and Z are defined as described in formula (II), R 6 is selected from halogens and is preferably bromine or iodine.

[0124] Additionally, the compounds of the present invention, and their stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives, have the structure of formula (VIII): [ka] In the formula, R 2 , R 3 , R 4 , w, ring A, Y, and Z are defined as described in formula (III), R 6 is selected from halogens and is preferably bromine or iodine.

[0125] Additionally, the compounds of the present invention, and their stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives, have the structure of formula (IX): [ka] In the formula, R 2 , R 3 , R 4 , w, ring A, Y, and Z are defined as described in formula (IV), R 6 is selected from halogens and is preferably bromine or iodine.

[0126] The present invention also provides pharmaceutical compositions comprising a compound of the present invention, a stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate, or isotopic derivative thereof.

[0127] The present invention also provides a pharmaceutical composition comprising a compound of the present invention, a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug, a solvate, or an isotopic derivative thereof, and a pharmaceutically acceptable excipient.

[0128] Another object of the present invention is to provide a compound of the present invention, a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug, a solvate or an isotopic derivative thereof, or a pharmaceutical composition of the present invention for use as a drug.

[0129] The object of the present invention also includes providing a compound of the present invention, a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug, a solvate or an isotopic derivative thereof, or a pharmaceutical composition of the present invention for preventing and / or treating an SOS1-mediated disease.

[0130] Another object of the present invention is to provide a compound of the present invention, a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug, a solvate or an isotopic derivative thereof, or a pharmaceutical composition of the present invention for preventing and / or treating a disease caused by a RAS mutation.

[0131] The object of the present invention also includes providing the use of the compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or the pharmaceutical composition of the present invention in the manufacture of a medicament for preventing and / or treating an SOS1-mediated disease.

[0132] In some embodiments, the SOS1-mediated disease is cancer or tumor, and related diseases.

[0133] In some embodiments, the SOS1-mediated disease is lung cancer (eg, non-small cell lung cancer (NSCLC)) and related diseases.

[0134] The object of the present invention also includes providing the use of the compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or the pharmaceutical composition of the present invention in the manufacture of a medicament for preventing and / or treating a disease caused by a RAS mutation.

[0135] In some embodiments, the disease caused by the RAS mutation is cancer or tumor, and related diseases.

[0136] In some embodiments, the disease caused by the RAS mutation is lung cancer (eg, non-small cell lung cancer (NSCLC)) and related diseases.

[0137] An object of the present invention also includes providing a method for preventing and / or treating an SOS1-mediated disease, which comprises administering to a patient a prophylactically and / or therapeutically effective dose of a compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or a pharmaceutical composition of the present invention.

[0138] Another object of the present invention is to provide a method for preventing and / or treating a disease caused by a RAS mutation, which comprises administering to a patient a prophylactically and / or therapeutically effective dose of a compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or a pharmaceutical composition of the present invention.

[0139] The object of the present invention also includes providing a non-diagnostic, non-therapeutic use of the compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or the pharmaceutical composition of the present invention for inhibiting the activity of guanine nucleotide exchange factors (GEFs) in vitro, wherein the guanine nucleotide exchange factor is selected from SOS1.

[0140] An object of the present invention also includes providing a non-diagnostic, non-therapeutic method for inhibiting the activity of a guanine nucleotide exchange factor in vitro, comprising administering to a subject an inhibitory effective dose of a compound of the present invention, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotopic derivative, or a pharmaceutical composition of the present invention, wherein the guanine nucleotide exchange factor is selected from SOS1. [Effects of the Invention]

[0141] The beneficial effects of the present invention are as follows: In the present invention, a series of compounds with novel structures have been designed, providing a new direction for the development of SOS1 inhibitors. In vitro enzyme activity inhibition studies have shown that these compounds have strong inhibitory effects on SOS1, making them promising compounds for preventing and / or treating SOS1-mediated diseases. Furthermore, these compounds exhibit significant inhibitory activity against NCI-H358 cell proliferation. The present invention also explores specific synthetic methods, which are simple and easy to operate, lending themselves to large-scale industrial production and use. DETAILED DESCRIPTION OF THE INVENTION

[0142] (Definition of terms) The terms "optional," "any," "optionally," or "may optionally..." mean that the subsequently described event or circumstance may occur, but does not necessarily occur, and the description includes instances where the event or circumstance occurs and instances where the event or circumstance does not occur.

[0143] Unless otherwise specified, the term "alkyl group" refers to a linear or branched monovalent saturated aliphatic hydrocarbon functional group generally having from 1 to 20 carbon atoms, preferably from 1 to 10 carbon atoms (i.e., C 1~10 alkyl), more preferably having 1 to 8 carbon atoms (i.e., C 1~8 alkyl), more preferably with 1 to 6 carbon atoms (i.e., C 1~6 For example, "C 1~6The term "alkyl group" refers to a functional group that is an alkyl group and has 1 to 6 carbon atoms in the carbon chain (specifically, 1, 2, 3, 4, 5, or 6). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, and n-octyl groups, but are not limited to these.

[0144] Unless otherwise specified, the term "alkenyl group" refers to a straight- or branched-chain monovalent unsaturated aliphatic hydrocarbon functional group having at least one double bond and generally having from 2 to 20 carbon atoms, preferably from 2 to 10 carbon atoms (i.e., C 2~10 alkenyl groups), more preferably having 2 to 8 carbon atoms (i.e., C 2~8 alkenyl groups), more preferably having 2 to 6 carbon atoms (i.e., C 2~6 For example, "C 2~6 The term "alkenyl group" refers to a functional group that is an alkenyl group and has 2 to 6 carbon atoms in the carbon chain (specifically, 2, 3, 4, 5, or 6). Non-limiting examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, and 1,3-butadienyl groups.

[0145] Unless otherwise specified, the term "alkynyl group" refers to a straight- or branched-chain monovalent unsaturated aliphatic hydrocarbon functional group having at least one triple bond and generally having from 2 to 20 carbon atoms, preferably from 2 to 10 carbon atoms (i.e., C 2~10 alkynyl groups), more preferably having 2 to 8 carbon atoms (i.e., C 2~8 alkynyl groups), more preferably with 2 to 6 carbon atoms (i.e., C 2~6 alkynyl group). For example, "C2~6 The term "alkynyl group" refers to an alkynyl group in which the functional group is an alkynyl group having 2 to 6 carbon atoms in the carbon chain (specifically, 2, 3, 4, 5, or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, and 1-butynyl groups.

[0146] Unless otherwise specified, the term "cycloalkyl group" refers to a mono- or polycyclic (e.g., fused, bridged, or spiro) monovalent aliphatic hydrocarbon functional group containing no unsaturated bonds and generally having from 3 to 12 carbon atoms (i.e., C 3~12 cycloalkyl), more preferably having 3 to 10 carbon atoms (i.e., C 3~10 cycloalkyl), more preferably 3 to 6 carbon atoms (i.e., C 3~6 cycloalkyl), 4 to 6 carbon atoms (i.e., C 4~6 cycloalkyl), 5 to 6 carbon atoms (i.e., C 5~6 Non-limiting examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethylcyclopentyl, dimethylcyclobutyl, and the like. Non-limiting examples of fused-ring cycloalkyl groups include, but are not limited to, decahydronaphthyl, octahydroindenyl, octahydropentalenyl, and the like. Non-limiting examples of bridged-ring cycloalkyl groups include: [ka] Non-limiting examples of spirocyclic cycloalkyl groups include: [ka] and the like, but are not limited to these.

[0147] Unless otherwise specified, the term "cycloalkenyl group" refers to a monovalent aliphatic hydrocarbon group, either monocyclic or polycyclic, containing at least one double bond and generally having from 3 to 12 carbon atoms (i.e., C 3~12 cycloalkenyl groups), more preferably 4 to 12 carbon atoms (i.e., C 4~12 cycloalkenyl groups), or 3 to 10 carbon atoms (i.e., C 3~10 cycloalkenyl group), more preferably 3 to 6 carbon atoms (i.e., C 3~6 cycloalkenyl groups), 4 to 6 carbon atoms (i.e., C 4~6 cycloalkenyl groups), 5 to 6 carbon atoms (i.e., C 5~6 Non-limiting examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, cyclohexadienyl, cycloheptatrienyl, cyclooctotrienyl, and the like.

[0148] Unless otherwise specified, the term "alkoxy group" refers to a functional group of "-O-alkyl group," where the definition of the alkyl group is the same as above, i.e., having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms (specifically, 1, 2, 3, 4, 5, or 6). Representative examples include, but are not limited to, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, 1-methylpropoxy group, 2-methylpropoxy group, tert-butoxy group, pentyloxy group, 1-methylbutoxy group, 2-methylbutoxy group, 3-methylbutoxy group, 1,1-dimethylpropoxy group, 1,2-dimethylpropoxy group, 2,2-dimethylpropoxy group, and 1-ethylpropoxy group.

[0149] Unless otherwise specified, the term "halogen" or "halo" refers to F, Cl, Br, I. The term "haloalkyl group" refers to an alkyl group, as defined above, in which one, two, or more hydrogen atoms or all hydrogen atoms have been replaced by halogen. Representative examples of haloalkyl groups are CCl3, CF3, CHCl2, CH2Cl, CH2Br, CH2I, CH2CF3, CF2CF3, and the like. Different notation systems may be used for haloalkyl groups, for example, "C 1~6 Haloalkyl group" is "halo C 1~6 The term "haloalkoxy group" refers to an alkoxy group, as defined above, in which one, two or more hydrogen atoms or all hydrogen atoms have been replaced by halogen. Representative examples of haloalkoxy groups are OCCl3, OCF3, OCHCl2, OCH2Cl, OCH2Br, OCHI, OCH2CF3, OCF2CF3, and the like. Different notation systems may be used for haloalkoxy groups, for example, "C 1~6 Haloalkoxy group" is "Halo C 1~6 The term "halocycloalkyl group" refers to a cycloalkyl group, as defined above, in which one, two or more or all hydrogen atoms have been replaced by halogen.

[0150] Unless otherwise specified, the term "heterocyclyl group" refers to a saturated or partially unsaturated, monocyclic or polycyclic (e.g., fused, bridged, or spiro) monovalent aliphatic ring system, non-aromatic as a whole, generally having 3 to 20 ring atoms, of which 1, 2, 3, or more are selected from N, O, or S, with the remaining ring atoms being C, preferably 3 to 12 ring atoms, more preferably 4 to 12 ring atoms, or 5 to 12 ring atoms, or 3 to 10 ring atoms, or 3 to 8 ring atoms, or 3 to 6 ring atoms, or 4 to 6 ring atoms, or 5 to 6 ring atoms. Preferably, the number of heteroatoms is 1 to 4, and more preferably 1 to 3 (i.e., 1, 2, or 3). Non-limiting examples of monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, imidazolidinyl, tetrahydrofuryl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, 2,5-dihydrofuryl, and pyridonyl. Polycyclic heterocyclyl groups include spirocyclic, fused-ring, and bridged-ring heterocyclyl groups. Non-limiting examples of fused-ring heterocyclyl groups include, but are not limited to, decahydroquinolinyl and octahydroindolyl. Non-limiting examples of bridged-ring heterocyclyl groups include: [ka] Non-limiting examples of spirocyclic heterocyclyl groups include: [ka] and the like, but are not limited to these.

[0151] Unless otherwise specified, the term "aryl group" refers to a monovalent, monocyclic or polycyclic (e.g., fused ring) aromatic ring system generally having 6 to 16 carbon atoms, or 6 to 14 carbon atoms, or 6 to 12 carbon atoms, preferably 6 to 10 carbon atoms. The term "aryl group" is interchangeable with the term "aromatic ring." Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, phenanthryl, or pyrenyl groups.

[0152] Unless otherwise specified, the term "heteroaryl group" refers to a monovalent aromatic ring system, typically a 5- to 12-membered structure, or preferably a 5- to 10-membered structure, a 5- to 8-membered structure, or more preferably a 5- to 6-membered structure, in which one, two, three, or more ring atoms are heteroatoms and the remaining atoms are carbon, each heteroatom independently selected from O, N, or S, preferably one, two, or three heteroatoms in number. The term "heteroaryl group" is interchangeable with the term "heteroaromatic ring." Non-limiting examples of heteroaryl groups include furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiadiazolyl, triazinyl, phthalazinyl, quinolinyl, isoquinolinyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuryl, benzothienyl, benzopi Examples include, but are not limited to, lysinyl, benzopyrimidinyl, benzopyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, and [1,2,4]triazolo[1,5-a]pyridinyl.

[0153] Unless otherwise specified, the term "hydroxy group" refers to an "-OH" functionality.

[0154] Unless otherwise specified, the term "cyano" refers to a "-CN" functionality.

[0155] Unless otherwise specified, the term "amino group" refers to an "-NH2" functional group. In some cases, the term "amino group" also refers to an amino group in which one or two hydrogen atoms are replaced by an alkyl group (e.g., C 1~6 Alkyl groups, preferably C 1~4 It refers to a functional group substituted with an alkyl.

[0156] Unless otherwise specified, the term "nitro group" refers to the "-NO2" functional group.

[0157] Unless otherwise specified, the term "formyl group" or "aldehyde group" refers to a "-C(=O)H" functional group.

[0158] Unless otherwise specified, the term "oxo group" refers to an "=O" functional group that is linked to a carbon atom, and the term "oxygen group" refers to an "=O" functional group that is linked to a heteroatom (e.g., a sulfur atom).

[0159] Unless otherwise specified, the term "pharmaceutically acceptable salt," "pharmaceutical salt," or "pharmaceutically acceptable salt" refers to a salt that is suitable, within the scope of reasonable medical judgment, for contact with the tissues of mammals, particularly humans, without undue toxicity, irritation, allergic response, etc., and for which the benefit-risk ratio is reasonable. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention, or the free base or free acid may be reacted separately with a suitable reagent to prepare the salt. For example, the free base may be reacted with a suitable acid.

[0160] Unless otherwise specified, the term "solvate" or "solvate" refers to a compound of the invention physically associated with one or more solvent molecules, whether organic or inorganic. Such physical association includes hydrogen bonding. In some cases, a solvate may be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. The solvent molecules in a solvate may be present in an ordered and / or disordered arrangement. A solvate may contain stoichiometric or non-stoichiometric solvent molecules. The term "solvate" covers solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, isopropanolates, and the like. Methods of solvation are well known in the art.

[0161] Unless otherwise specified, the compounds of the present invention also include their "isotopic derivatives" (such as deuterated derivatives), and the term "isotopic derivative" refers to compounds of the present invention that may exist in isotopically traceable or enriched form and contain one or more atoms whose atomic mass or mass number is different from that of the most abundant atom occurring in nature. The isotopes may be radioactive or non-radioactive. Generally, the isotopes used for isotopically labeling are hydrogen isotopes. 2 H(D) and 3 H(T), carbon isotope 13 C and 14 C, chlorine isotope 35 Cl and 37 Cl, fluorine isotopes 18 F, an iodine isotope 123 I and 125 I, nitrogen isotope 13 N and 15 N, oxygen isotopes 15 O. 17 O and 18 O, and sulfur isotopes 35 These isotopically labeled compounds can be used to study the tissue distribution of pharmaceutical molecules, among others. 3 H and 13C is widely used because it is easy to label and detect. Some heavy isotopes, such as deuterium ( 2 Substitution with H) provides therapeutic benefits by increasing metabolic stability and half-life, thereby enabling dose reduction. Isotopically labeled compounds are generally synthesized from labeled starting materials using conventional synthetic techniques, similar to non-isotopically labeled compounds.

[0162] Unless otherwise specified, the term "prodrug" refers to a drug that is converted into the parent drug in vivo. Prodrugs are generally useful because, in some cases, they may be easier to administer than the parent drug. For example, they may be bioavailable upon oral administration, whereas the parent drug may not. Compared to the parent drug, a prodrug may have improved solubility in pharmaceutical compositions.

[0163] Unless otherwise specified, the term "optical isomers" refers to substances that have the exact same molecular structure and similar physicochemical properties, but different optical rotations.

[0164] Unless otherwise specified, the term "stereoisomer" refers to compounds that have the same chemical constitution but differ in the way their atoms or functional groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotational isomers), geometric isomers (cis / trans isomers), atropisomers, and the like. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, or diastereomers due to the differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization.

[0165] Unless otherwise specified, the structural formulae depicted in the present invention include all isomeric forms (enantiomers, diastereomers, geometric isomers (or conformational isomers), etc., such as R, S configurations containing asymmetric centers, (Z), (E) isomers with double bonds, and (Z), (E) conformational isomers. Thus, any single stereochemical isomer or mixture of enantiomers, diastereomers, or geometric isomers (or conformational isomers) of the compounds of the present invention are within the scope of the present invention.

[0166] Unless otherwise specified, the terms "optionally substituted," "optionally substituted with," and "optionally substituted with" mean that the hydrogen at a substitutable site of the functional group is not substituted or is substituted with one or more substituents, and the substituents include halogen, hydroxy, mercapto, cyano, nitro, amino, azide, oxo, carboxy, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~10 Cycloalkyl groups, 3- to 10-membered heterocyclyl groups, C 6~14 The substituents are preferably selected from the group consisting of an aryl group and a 5- to 10-membered heteroaromatic ring group, among which the C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~10 Cycloalkyl groups, 3- to 10-membered heterocyclyl groups, C 6~14 The aryl group and the 5- to 10-membered heteroaromatic ring group are both substituted with halogen, hydroxyl group, amino group, cyano group, C 1~6 Alkyl group or C 1~6 It may be optionally substituted with one or more substituents selected from alkoxy groups. [Example]

[0167] The present invention will be further described below with reference to specific examples. Note that these examples do not limit the scope of the present invention but are merely intended to illustrate the present invention. In the following examples, test methods for which specific conditions are not specified are performed under normal conditions or conditions recommended by the manufacturer. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred methods and materials described herein are merely illustrative.

[0168] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or / and liquid chromatography mass spectrometry (LC-MS) or / and high performance liquid chromatography (HPLC). The NMR measurement is performed using a Bruker AVANCE III 600MHz instrument, the LC-MS measurement is performed using a WATERS ACQUITY UPLC H-Class PLUS or / and SQD2 instrument, and the HPLC measurement is performed using a WATERS e2695_2998 or / and Agilent 1100 instrument.

[0169] In the examples of the present invention, the starting materials are existing and may be purchased from the market or may be synthesized by conventional methods in the art.

[0170] Production Example 1: Synthesis of Intermediate A [ka] Synthesis of intermediate A-2: 1-(3-Nitro-5-trifluoromethyl-phenyl)-ethanone (10.00 g, 43.0 mmol) was dissolved in ethanol (200 mL), followed by the addition of iron powder (7.22 g, 129.0 mmol) and concentrated hydrochloric acid (50 mL). The mixture was then reacted at 80 °C for 2 h. After LC-MS monitoring showed no remaining starting material, the mixture was cooled and filtered. The filtrate was evaporated under reduced pressure to remove the solvent. The residue was purified by column chromatography (dichloromethane:methanol = 50:1 to 20:1) to give A-2 (8.12 g, 40.0 mmol, 92%). ESI-MS: m / z 204.12 [M+H] + .

[0171] Synthesis of intermediate A-3: A-2 (27.02 g, 133.0 mmol) was dissolved in tetrahydrofuran (50 mL), followed by the addition of (R)-(+)-2-methyl-2-propanesulfinamide (24.24 g, 200.0 mmol) and Ti(OEt)4 (91.02 g, 399 mmol). The reaction mixture was heated at 80 °C for 2 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water, and the precipitate was dissolved in ethyl acetate and filtered. The filtrate was evaporated under reduced pressure to remove the solvent. The residue was purified by column chromatography (dichloromethane:methanol = 50:1 to 20:1) to give product A-3 (34.65 g, 113.1 mmol, 85%). ESI-MS: m / z 307.12 [M+H] + .

[0172] Synthesis of intermediate A-4: A-3 (34.65 g, 113.1 mmol) was dissolved in tetrahydrofuran (50 mL) and sodium borohydride (6.42 g, 169.7 mmol) was added at -78 °C. The reaction mixture was slowly heated to room temperature and monitored by LC-MS to confirm no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated brine (100 mL x 2), and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (dichloromethane:methanol = 50:1 to 20:1) to give A-4 (28.43 g, 92.2 mmol, 82%). ESI-MS: m / z 309.10 [M+H] + .

[0173] Synthesis of intermediate A: A-4 (28.43 g, 92.2 mmol) was dissolved in a solution of hydrochloric acid and dioxane (50 mL), and the mixture was allowed to react at room temperature for 2 hours. LC-MS showed no remaining starting material, and the solvent was evaporated under reduced pressure to give Intermediate A, which was then directly used in the next step in the form of hydrochloride. ESI-MS: m / z 205.22 [M+H] + .

[0174] The following intermediates may be obtained by referring to the synthesis method of intermediate A or by referring to the related synthesis method of CN110167928A. If necessary, the crude product is purified by chromatography. [Table 1]

[0175] Example 1: Synthesis of Compound 1 [ka] Synthesis of intermediate 1-1: 2-Amino-6-chloronicotinic acid (5.00 g, 29.0 mmol) was dissolved in 80 mL of methanol and cooled to 0 °C. 16 mL of concentrated sulfuric acid was added and the mixture was incubated at 80 °C for 5 h. LC-MS showed no remaining starting material. 100 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:1) to give 1-1 (5.03 g, 93% yield). ESI-MS: m / z 187.02 [M+H] + .

[0176] Synthesis of intermediate 1-2: 1-1 (5.03 g, 26.9 mmol) was dissolved in acetonitrile (80 mL), followed by the addition of N-bromosuccinimide (7.17 g, 40.3 mmol). The reaction was allowed to proceed at room temperature for 1.5 hours, and LC-MS showed no remaining starting material. The reaction was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 1-2 (6.85 g, 96% yield). ESI-MS: m / z 265.10 / 267.13 [M+H] + .

[0177] Synthesis of intermediates 1-3: 1-2 (6.85 g, 25.8 mmol) was dissolved in 80 mL of acetonitrile, followed by the addition of 15 mL of methanesulfonic acid. The mixture was incubated at 130 °C for 8 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 1-3 (1.51 g, 21% yield). ESI-MS: m / z 274.02 / 275.98 [M+H] + .

[0178] Synthesis of intermediates 1-4: 1-3 (1.51 g, 5.50 mmol) was dissolved in 50 mL of ethanol, followed by the addition of hydrazine monohydrate (1.76 g, 55.0 mmol). The reaction mixture was heated at 80 °C for 2 h, and LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was directly used for the next step. ESI-MS: m / z 270.01 / 272.03 [M+H] + .

[0179] Synthesis of intermediates 1-5: 1-4 was dissolved in 30 mL of chloroform, followed by the addition of 10 mL of triethyl orthoformate. The reaction mixture was heated at 80 °C for 2 hours, and monitored by LC-MS to confirm that no raw material remained. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated brine (100 mL x 2), and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 1-5 (1.00 g, 65% yield over two steps). ESI-MS: m / z 280.00 / 282.02 [M+H] + .

[0180] Synthesis of intermediates 1-6: 1-5 (1.00 g, 3.60 mmol) was dissolved in 50 mL of toluene, followed by the addition of diisopropylethylamine (464 mg, 3.60 mmol) and phosphoryl chloride (2.76 g, 18.0 mmol). The mixture was heated at 100 °C for 2 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:1) to give 1-6 (800 mg, 75% yield). ESI-MS: m / z 298.03 / 300.02 [M+H] + .

[0181] Synthesis of intermediates 1-7: 1-6 (800 mg, 2.68 mmol) was dissolved in 30 mL of N,N-dimethylformamide, followed by the addition of diisopropylethylamine (697 mg, 5.40 mmol) and intermediate B (612 mg, 3.24 mmol). The mixture was heated at 120 °C for 2 h, and LC-MS confirmed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:2) to give 1-7 (798 mg, 66% yield). ESI-MS: m / z 451.02 / 453.07 [M+H] + .

[0182] Synthesis of intermediates 1-8: 1-7 (100 mg, 0.22 mmol) was dissolved in dioxane (40 mL) and water (10 mL). Potassium hydroxide (25 mg, 0.44 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (10 mg, 0.02 mmol) were added. The whole system was stirred at 100 °C for 3 h. When no raw material remained as monitored by TLC, 50 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. 1-8 was obtained (40 mg, 47% yield) by column chromatography (dichloromethane:methanol = 60:1 to 20:1). ESI-MS: m / z 389.15 [M+H] + .

[0183] Synthesis of Compound 1: 1-8 (40 mg, 0.10 mmol) was dissolved in N,N-dimethylformamide (15 mL), followed by the addition of (R)-3-(p-toluenesulfonyl)oxytetrahydrofuran (30 mg, 0.12 mmol) and cesium carbonate (65 mg, 0.20 mmol). The mixture was stirred at 80 °C for 3 h. After TLC showed no remaining starting material, the reaction mixture was added with 30 mL of water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The product was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 1 (30 mg, 65% yield). ESI-MS: m / z 459.25 [M+H] + . 1H NMR(600MHz,DMSO-d6):δ 9.59(s,1H),8.40(d,J=7.2Hz,1H),7.82(s,1H),7.77(d,J=7.2Hz,1H),7.63-7.58(m,2H),7.46(s,1H),5.71-5.64(m,1H),5.4 7-5.45(m,1H),4.05-4.03(m,1H),3.98-3.94(m,2H),3.88-3.84(m,1H),2.46(s,3H),2.42-2.37(m,2H),1.66(d,J=7.2Hz,3H).

[0184] Example 2: Synthesis of Compound 2 [ka] Synthesis of intermediate 2-1: 1-7 (100 mg, 0.22 mmol) was dissolved in dioxane (30 mL). N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (84 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol), and cesium carbonate (143 mg, 0.44 mmol) were added. The whole system was stirred at 100 °C for 3 h. After TLC showed no remaining raw materials, 50 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. 2-1 (100 mg, 82% yield) was obtained by column chromatography (dichloromethane:methanol = 60:1 to 20:1). ESI-MS: m / z 554.19 [M+H] + .

[0185] Synthesis of intermediate 2-2: 2-1 (100 mg, 0.18 mmol) was dissolved in 4 M hydrochloric acid-ethyl acetate solution (10 mL) and stirred at room temperature for 2 hours. When no starting material remained as monitored by TLC, the solvent was removed under reduced pressure to give residue 2-2, which was directly used for the next step. ESI-MS: m / z 454.16 [M+H] + .

[0186] Synthesis of compound 2: 2-2 was dissolved in dichloromethane (10 mL), followed by the addition of triethylamine (36 mg, 0.36 mmol) and acetic anhydride (22 mg, 0.22 mmol). The mixture was stirred at room temperature for 2 hours. TLC showed no remaining starting material. The reaction mixture was quenched with water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The product was purified by column chromatography (dichloromethane:methanol = 60:1 to 15:1) to give compound 2 (50 mg, 56% yield). ESI-MS: m / z 496.17 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 9.59(d,J=3.6Hz,1H),8.75(dd,J=7.8Hz,J=7.8Hz,1H),8.03(d,J=5.4Hz,1H),7.83(s,1H),7.78(d,J=7.2Hz,1H),7.63-7.58(m,2H),7.49-7. 47(m,1H),5.72-5.68(m,1H),4.33-4.26(m,2H),3.77-3.73(m,2H),2. 87-2.63(m,2H),2.48(s,3H),2.13-2.08(m,3H),1.66(d,J=7.2Hz,3H).

[0187] Example 3: Synthesis of Compound 3 [ka] 1-7 (100 mg, 0.22 mmol) was dissolved in N-methylpyrrolidone (30 mL). N-methylpiperazine (27 mg, 0.27 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), and sodium tert-butoxide (42 mg, 0.44 mmol) were added. The mixture was stirred at 120 °C for 3 h. After TLC monitoring revealed no remaining starting material, the reaction mixture was added with 50 mL of water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The product was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 3 (41 mg, 40% yield). ESI-MS: m / z 471.18 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 9.53(s,1H),8.42(d,J=7.8Hz,1H),7.82(s,1H),7.77(d,J=7.2Hz,1H),7.61-7.57(m,2H),7.10(s,1H),5 .68-5.65(m,1H),3.65-3.60(m,4H),2.63-2.59(m,4H),2.43(s,3H),2.30(s,3H),1.65(d,J=7.2Hz,3H).

[0188] Example 4: Synthesis of Compound 4 [ka] 1-7 (100 mg, 0.22 mmol) was dissolved in N-methylpyrrolidone (30 mL). Subsequently, morpholine (24 mg, 0.27 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), and sodium tert-butoxide (42 mg, 0.44 mmol) were added. The entire system was stirred at 120 °C for 3 h. After TLC monitoring revealed no remaining starting material, the reaction mixture was added with 50 mL of water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Compound 4 was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 4 (50 mg, 50% yield). ESI-MS: m / z 458.16 [M+H]. + . 1 H NMR(600MHz,DMSO-d6):δ 9.53(s,1H),8.43(d,J=7.8Hz,1H),7.82(s,1H),7.77(d,J=6.6Hz,1H),7.62-7.58(m,2H),7.13(s ,1H),5.70-5.65(m,1H),3.88-3.87(m,4H),3.61-3.59(m,4H),2.43(s,3H),1.65(d,J=7.2Hz,3H).

[0189] Example 5: Synthesis of Compound 5 [ka] Synthesis of intermediate 5-1: 4,6-Dichloro-2-methylpyrimidine-5-carbaldehyde (2.00 g, 10.47 mmol) was dissolved in tetrahydrofuran (20 mL), followed by the addition of (ethoxycarbonylmethylene)triphenylphosphorane (5.47 g, 15.71 mmol) and triethylamine (2.12 g, 20.94 mmol). The reaction mixture was heated at 80 °C for 6 h. LC-MS showed no remaining starting material. The reaction mixture was directly purified by column chromatography (n-hexane:ethyl acetate = 20:1 to 10:1) to give 5-1 (1.71 g, 6.54 mmol, 63% yield). ESI-MS: m / z 260.85 [M+H]+ .

[0190] Synthesis of intermediate 5-2: 5-1 (1.71 g, 6.54 mmol) was dissolved in N,N-dimethylformamide (20 mL), followed by the addition of tert-butyl (2-aminoethyl)carbamate (1.26 g, 7.85 mmol) and triethylamine (1.32 g, 13.08 mmol). The mixture was allowed to react at room temperature for 12 h. LC-MS monitoring revealed no remaining starting material. Water (30 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (30 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin-layer chromatography (n-hexane:ethyl acetate = 10:1 to 3:1) to give 5-2 (2.30 g, 5.99 mmol, 92% yield). ESI-MS: m / z 385.15 [M+H] + .

[0191] Synthesis of intermediate 5-3: 5-2 (2.30 g, 5.99 mmol) was dissolved in methanol (30 mL), followed by the addition of sodium methoxide (3.6 mL, 17.97 mmol, 30% w / w in methanol). The mixture was allowed to react at room temperature for 12 h. A solid precipitated from the reaction mixture. LC-MS showed no remaining starting material. Water (10 mL) was added to the reaction mixture, which was then filtered to give a white solid, 5-3 (1.60 g, 4.79 mmol, 80% yield). ESI-MS: m / z 335.07 [M+H] + .

[0192] Synthesis of intermediate 5-4: 5-3 (1.60 g, 4.79 mmol) was dissolved in dichloromethane (30 mL), followed by the addition of bromine (1.15 g, 7.19 mmol). The reaction mixture was allowed to react at room temperature for 12 h. LC-MS showed no remaining starting material. The reaction mixture was directly purified by column chromatography (n-hexane:ethyl acetate = 5:1 to 3:1) to give 5-4 (1.80 g, 4.36 mmol, 91% yield). ESI-MS: m / z 412.98 / 415.00 [M+H] + .

[0193] Synthesis of intermediate 5-5: 5-4 (1.80 g, 4.36 mmol) was dissolved in dichloromethane (20 mL), followed by the addition of 5 mL of trifluoroacetic acid. The reaction mixture was allowed to react at room temperature for 4 hours. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure. 15 mL of water was added to the residue, and the pH was adjusted to 8-9 with saturated aqueous sodium carbonate. Extraction was performed with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure to give 5-5 (0.90 g, 2.88 mmol, 66% yield). ESI-MS: m / z 312.92 / 314.91 [M+H] + .

[0194] Synthesis of intermediate 5-6: 5-5 (0.90 g, 2.88 mmol) was dissolved in toluene (20 mL), followed by the slow addition of trimethylaluminum (1.9 mL, 3.75 mmol, 2.0 M in toluene). The reaction mixture was heated at 120 °C for 5 h, and monitored by LC-MS until no starting material remained. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and evaporated under reduced pressure to remove toluene. 15 mL of water was added to the residue, which was then extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (20 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure to give 5-6 (0.59 g, 2.01 mmol, 70% yield). ESI-MS: m / z 294.87 / 296.83 [M+H] + .

[0195] Synthesis of intermediates 5-7: 5-6 (0.59 g, 2.01 mmol) was dissolved in dichloromethane (10 mL) and boron tribromide (2.52 g, 10.05 mmol) was added slowly over an ice bath. Upon completion, the ice bath was removed and the reaction mixture was allowed to react at room temperature for 72 h. LC-MS showed no remaining starting material. The reaction was quenched by the slow addition of sodium carbonate solution over an ice bath. A solid precipitated and was filtered to give 5-7 (0.46 g, 1.64 mmol, 82% yield). ESI-MS: m / z 280.82 / 282.84 [M+H] + .

[0196] Synthesis of intermediates 5-8: 5-7 (50 mg, 0.18 mmol) was dissolved in N,N-dimethylformamide (15 mL). (R)-1-[3-(trifluoromethyl)phenyl]ethylamine hydrochloride (61 mg, 0.27 mmol), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (102 mg, 0.23 mmol), and 1,8-diazabicyclo[5.4.0]-7-undecene (82 mg, 0.54 mmol) were added. The mixture was incubated at room temperature for 8 h. After no remaining starting material was detected by LC-MS, the reaction mixture was added with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (30 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol=20:1) to give 5-8 (40 mg, 0.089 mmol, 49% yield). ESI-MS: m / z 451.94 / 453.94 [M+H] + .

[0197] Synthesis of compound 5: 5-8 (40 mg, 0.089 mmol) was dissolved in dioxane (10 mL) and water (2 mL). Subsequently, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (31 mg, 0.133 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (13 mg, 0.018 mmol), and cesium carbonate (58 mg, 0.178 mmol) were added. The reaction mixture was heated at 100 °C for 4 h. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin-layer chromatography (dichloromethane:methanol:triethylamine=100:2:1) to give compound 5 (17 mg, 0.035 mmol, 40% yield). ESI-MS: m / z 481.11 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 8.37(s,1H),8.32(s,1H),7.78-7.73(m,3H),7.60-7.59(m,2H),7.21(s,1H),6.81(d,J=12.0Hz,1H),5.61- 5.59(m,1H),4.12(t,J=6.0Hz,2H),3.97(t,J=6.0Hz,2H),3.46(s,3H),2.31(s,3H),1.59(d,J=6.0Hz,3H).

[0198] Example 6: Synthesis of Compound 6 [ka] Synthesis of intermediate 6-1: 5-7 (100 mg, 0.36 mmol) was dissolved in N,N-dimethylformamide (15 mL). (R)-3-(1-aminoethyl)-5-(trifluoromethyl)phenylamine (110 mg, 0.54 mmol), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (207 mg, 0.47 mmol), and 1,8-diazabicyclo[5.4.0]-7-undecene (164 mg, 1.08 mmol) were added. The mixture was incubated at room temperature for 8 h. After no remaining starting material was detected by LC-MS, the reaction mixture was added with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (30 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol=20:1) to give 6-1 (60 mg, 36% yield). ESI-MS: m / z 466.91 / 469.12 [M+H] + .

[0199] Synthesis of compound 6: 6-1 (60 mg, 0.128 mmol) was dissolved in dioxane (10 mL) and water (2 mL). 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (45 mg, 0.191 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (19 mg, 0.026 mmol), and cesium carbonate (84 mg, 0.258 mmol) were added. The reaction mixture was heated at 100 °C for 4 h. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol:triethylamine=50:2:1) to give compound 6 (20 mg, 31% yield). ESI-MS: m / z 496.08 [M+H] + . 1H NMR(600MHz,DMSO-d6):δ 8.30(s,1H),8.13(d,J=6.0Hz,1H),7.72(d,J=6.0Hz,1H),7.32(s,1H),6.88(d,J=6.0Hz,1H),6.84-6.82(m,2H),6.71(s,1 H),5.57(s,2H),5.50-5.47(m,1H),4.07-4.05(m,2H),3.98-3.95(m,2H),3.45(s,3H),2.31(s,3H),1.52(d,J=6.0Hz,3H).

[0200] Example 7: Synthesis of Compound 7 [ka] Synthesis of intermediate 7-1: 5-7 (100 mg, 0.36 mmol) was dissolved in N,N-dimethylformamide (15 mL). (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethylamine hydrochloride (121 mg, 0.54 mmol), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (205 mg, 0.47 mmol), and 1,8-diazabicyclo[5.4.0]-7-undecene (163 mg, 1.08 mmol) were added. The mixture was incubated at room temperature for 8 h. After no remaining starting material was detected by LC-MS, the reaction mixture was added with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (30 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol=20:1) to give 7-1 (110 mg, 68% yield). ESI-MS: m / z 451.93 / 453.93 [M+H] + .

[0201] Synthesis of compound 7: 7-1 (110 mg, 0.243 mmol) was dissolved in dioxane (10 mL) and water (2 mL). Subsequently, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (86 mg, 0.366 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (36 mg, 0.049 mmol), and cesium carbonate (159 mg, 0.488 mmol) were added. The reaction mixture was heated at 100 °C for 4 h. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol:triethylamine=100:2:1) to give compound 7 (50 mg, 43% yield). ESI-MS: m / z 481.09 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 8.33(s,1H),8.18(d,J=6.0Hz,1H),7.72(d,J=6.0Hz,1H),7.66-7.64(m,1H),7.52-7.50(m,1H),7.33-7.32(m,2H),7.24(t ,J=54.0Hz,1H),6.91-6.89(m,1H),5.75-5.70(m,1H),4.02-3.95(m,4H),3.45(s,3H),3.25(s,3H),1.58(d,J=6.0Hz,3H).

[0202] Example 8: Synthesis of Compound 8 [ka] Synthesis of intermediate 8-1: 5-7 (100 mg, 0.36 mmol) was dissolved in N,N-dimethylformamide (15 mL), followed by the addition of intermediate G (112 mg, 0.54 mmol), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (205 mg, 0.47 mmol), and 1,8-diazabicyclo[5.4.0]-7-undecene (163 mg, 1.08 mmol). The mixture was allowed to react at room temperature for 8 h. After monitoring by LC-MS, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (30 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin-layer chromatography (dichloromethane:methanol = 20:1) to give 8-1 (127 mg, 75% yield). ESI-MS: m / z 470.98 / 472.98[M+H] + .

[0203] Synthesis of compound 8: 8-1 (113 mg, 0.24 mmol) was dissolved in dioxane (10 mL) and water (2 mL). 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (86 mg, 0.366 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (36 mg, 0.049 mmol), and cesium carbonate (159 mg, 0.488 mmol) were added. The reaction mixture was heated at 100 °C for 4 h. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol:triethylamine=100:2:1) to give compound 8 (55 mg, 46% yield). ESI-MS: m / z 499.11 [M+H] + . 1H NMR(600MHz,DMSO-d6):δ 8.95(s,1H),8.80(s,1H),7.87-7.85(m,2H),7.67(dd,J=6.6Hz,J=6.6Hz,1H),7.39(dd,J=7.8Hz,J=7.8Hz,1H),6.91 (s,1H),6.65(d,J=6.6Hz,1H),5.77-5.71(m,1H),4.41-4.34(m,4H),3.50(s,3H),2.34(s,3H),1.62(d,J=6.0Hz,3H).

[0204] Example 9: Synthesis of Compound 9 [ka] Synthesis of intermediate 9-1: 3-Amino-2-chloroisonicotinic acid (5.00 g, 29.0 mmol) was dissolved in methanol (80 mL), cooled to 0 °C, and then concentrated sulfuric acid (16 mL) was added. The reaction mixture was heated at 80 °C for 5 h. LC-MS showed no remaining starting material. Water (100 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:1) to give 9-1 (5.00 g, 92% yield). ESI-MS: m / z 187.02 [M+H] + .

[0205] Synthesis of intermediate 9-2: 9-1 (5.00 g, 26.8 mmol) was dissolved in acetonitrile (80 mL), followed by the addition of N-bromosuccinimide (7.17 g, 40.3 mmol). The reaction was allowed to proceed at room temperature for 1.5 hours, and LC-MS showed no remaining starting material. The reaction was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 9-2 (6.85 g, 96% yield). ESI-MS: m / z 265.10 / 267.12 [M+H] + .

[0206] Synthesis of intermediate 9-3: 9-2 (6.85 g, 25.8 mmol) was dissolved in acetonitrile (80 mL), followed by the addition of methanesulfonic acid (15 mL). The mixture was incubated at 130 °C for 8 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 9-3 (1.51 g, 21% yield). ESI-MS: m / z 274.02 / 276.11 [M+H] + .

[0207] Synthesis of intermediate 9-4: 9-3 (1.51 g, 5.50 mmol) was dissolved in ethanol (50 mL), followed by the addition of hydrazine monohydrate (1.76 g, 55.0 mmol). The reaction mixture was heated at 80 °C for 2 h, and LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was directly used for the next step. ESI-MS: m / z 270.02 / 271.06 [M+H] + .

[0208] Synthesis of intermediate 9-5: 9-4 was dissolved in chloroform (30 mL), followed by the addition of triethyl orthoformate (10 mL). The reaction mixture was heated at 80 °C for 2 hours. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:3) to give 9-5 (1.00 g, 65% yield). ESI-MS: m / z 280.02 / 282.14 [M+H] + .

[0209] Synthesis of intermediate 9-6: 9-5 (1.00 g, 3.60 mmol) was dissolved in toluene (50 mL), followed by the addition of diisopropylethylamine (465 mg, 3.60 mmol) and phosphoryl chloride (2.76 g, 18.0 mmol). The mixture was heated at 100 °C for 2 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:1) to give 9-6 (800 mg, 74% yield). ESI-MS: m / z 298.02 / 300.20 [M+H] + .

[0210] Synthesis of intermediate 9-7: 9-6 (400 mg, 1.34 mmol) was dissolved in N,N-dimethylformamide (30 mL), followed by the addition of diisopropylethylamine (349 mg, 2.70 mmol) and intermediate D (384 mg, 2.02 mmol). The reaction mixture was heated at 120 °C for 2 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:2) to give 9-7 (397 mg, 66% yield). ESI-MS: m / z 451.02 / 453.09 [M+H] + .

[0211] Synthesis of compound 9: 9-7 (397 mg, 0.88 mmol) was dissolved in dioxane (30 mL), followed by the addition of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (249 mg, 1.06 mmol), tetrakis(triphenylphosphine)palladium(0) (104 mg, 0.09 mmol), and cesium carbonate (574 mg, 1.76 mmol). The reaction mixture was stirred at 0°C for 3 hours. When no starting material remained as monitored by TLC, water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 9 (253 mg, 60% yield). ESI-MS: m / z 480.11 [M+H] + . 1H NMR (600 MHz, DMSO-d): δ 9.34(s,1H),8.58(d,J=7.2Hz,1H),7.98(d,J=6.6Hz,1H),7.94(s,1H),7.70(dd ,J=7.2Hz,J=7.2Hz,1H),7.53(dd,J=6.6Hz,J=7.2Hz,1H),7.32(dd,J=7.8Hz,J= 7.8Hz,1H),7.26(t,J=54.6Hz,1H),6.87(d,J=1.8Hz,1H),6.66(dd,J=1.8Hz,J= 2.4Hz, 1H), 5.81-5.79 (m, 1H), 3.56 (s, 3H), 2.49 (s, 3H), 1.63 (d, J=6.6Hz, 3H).

[0212] Example 10: Synthesis of Compound 10 [ka] Synthesis of intermediate 10-1: 9-6 (400 mg, 1.34 mmol) was dissolved in N,N-dimethylformamide (30 mL), followed by the addition of diisopropylethylamine (349 mg, 2.70 mmol) and intermediate G (418 mg, 2.02 mmol). The reaction mixture was heated at 120 °C for 2 h. LC-MS showed no remaining starting material. The reaction mixture was quenched with ice water and extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:2) to give 10-1 (415 mg, 66% yield). ESI-MS: m / z 469.02 / 471.09 [M+H] + .

[0213] Synthesis of compound 10: 10-1 (415 mg, 0.88 mmol) was dissolved in dioxane (30 mL), and then 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (249 mg, 1.06 mmol), tetrakis(triphenylphosphine)palladium(0) (104 mg, 0.09 mmol), and cesium carbonate (574 mg, 1.76 mmol) were added. The whole system was cooled to 10 The reaction mixture was stirred at 0°C for 3 hours. When no starting material remained as monitored by TLC, water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 10 (250 mg, 57% yield). ESI-MS: m / z 498.11 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 9.34(s,1H),8.64(d,J=6.6Hz,1H),7.98(d,J=6.6Hz,1H),7.94(s,1H),7.83(dd,J=7.2Hz,J=7.2Hz,1H),7.67(dd,J=6.6Hz,J=7.2Hz,1H),7.38(dd, J=7.8Hz,J=7.8Hz,1H),6.87(d,J=1.8Hz,1H),6.67(dd,J=1.8Hz,J=1.8Hz ,1H),5.78-5.74(m,1H),3.56(s,3H),2.47(s,3H),1.64(d,J=6.6Hz,3H).

[0214] Example 11: Synthesis of Compound 11 [ka] Synthesis of intermediate 11-1: Intermediate 1-3 (0.68 g, 2.48 mmol) was dissolved in absolute ethanol (10 mL), and aminoacetaldehyde diethyl acetal (0.49 g, 3.72 mmol) and N,N-diisopropylethylamine (0.64 g, 4.96 mmol) were added. The mixture was refluxed for 5 hours, and monitored by LC-MS to determine whether any starting material remained. The reaction mixture was cooled, saturated brine was added, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give 11-1 (0.83 g, 90% yield). ESI-MS: m / z 371.58 / 373.32 [M+H] + .

[0215] Synthesis of intermediate 11-2: Intermediate 11-1 (0.83 g, 2.24 mmol) was dissolved in concentrated sulfuric acid and heated to 65 °C for 2 hours. When no starting material remained as monitored by LC-MS, the reaction mixture was slowly added dropwise to saturated sodium bicarbonate solution to quench the reaction. The mixture was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give 11-2 (0.40 g, 63% yield). ESI-MS: m / z 279.10 / 301.14 [M+H] + .

[0216] Synthesis of intermediate 11-3: Intermediate 11-2 (0.26 g, 0.94 mmol) was dissolved in N,N-dimethylformamide (5 mL), and Intermediate B (0.27 g, 1.22 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (0.74 g, 1.41 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. When no starting material remained as monitored by LC-MS, the reaction mixture was added to saturated brine, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give 11-3 (0.18 g, 43% yield). ESI-MS: m / z 449.90 / 451.91 [M+H] + .

[0217] Synthesis of intermediate 11-4: 11-3 (180 mg, 0.40 mmol) was dissolved in dioxane (40 mL) and water (10 mL). Potassium hydroxide (67 mg, 1.2 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (10 mg, 0.02 mmol) were added. The whole system was stirred at 100 °C for 3 h. When no starting material remained as monitored by TLC, 50 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. 11-4 (71 mg, 46%) was obtained by column chromatography (dichloromethane:methanol = 60:1 to 20:1). ESI-MS: m / z 388.07 [M+H] + .

[0218] Synthesis of compound 11: 11-4 (71 mg, 0.16 mmol) was dissolved in N,N-dimethylformamide (15 mL), followed by the addition of (R)-3-(p-toluenesulfonyl)oxytetrahydrofuran (47 mg, 0.19 mmol) and cesium carbonate (104 mg, 0.32 mmol). The mixture was stirred at 80 °C for 3 h. After TLC showed no remaining starting material, 30 mL of water was added to the reaction mixture, followed by extraction with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The product was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give compound 11 (48 mg, 66% yield). ESI-MS: m / z 458.32 [M+H] + . 1H NMR(600MHz,DMSO-d6):δ 8.29(s,1H),7.87(d,J=4.8Hz,1H),7.82(d,J=6.3Hz,1H),7.67-7.53(m,4H),5.69(p,J=7.2Hz,1H),5.51(d,J=6.5Hz,1H),4 .05(dt,J=10.8,3.6Hz,1H),3.97-3.91(m,2H),3.84(td,J=8.3,4.5Hz,1H),2.45(s,3H),1.68(d,J=7.1Hz,3H),1.23(m,2H).

[0219] Examples 12 to 30: The compounds of the following Examples 12 to 30 may be obtained by referring to the synthesis methods of Examples 1 to 11. [Table 2-1] [Table 2-2] [Table 2-3]

[0220] Example 31: Synthesis of Compound 31 [ka] Synthesis of compound 31: Intermediate 7-1 (99 mg, 0.22 mmol) from Example 7 was dissolved in dioxane (30 mL). 1-acetyl-5,6-dihydro-2H-pyridine-4-boronic acid pinacol ester (68 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol), and cesium carbonate (143 mg, 0.44 mmol) were added. The whole system was stirred at 100 °C for 3 hours. When no raw material remained as monitored by TLC, 50 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by column chromatography (dichloromethane:methanol = 60:1 to 15:1) to obtain compound 31 (69 mg, 0.14 mmol, 64% yield). ESI-MS: m / z 497.24 [M+H] + . 1 H NMR (600 MHz, DMSO-d): δ 8.23(s,1H),8.00(s,1H),7.64(dd,J=7.2Hz,J=7.2Hz,1H),7.50(dd,J=7.2H z,J=7.2Hz,1H),7.32-7.29(m,1H),7.23(t,J=54.0Hz,1H),6.82(d,J=87.6Hz ,1H),5.75-5.70(m,1H),4.22-4.02(m,4H),3.95-3.92(m,2H),3.67-3.62(m, 2H),2.50(s,3H),2.26(s,3H),2.06(d,J=24.6Hz,2H),1.56(d,J=6.6Hz,3H).

[0221] Examples 32 to 92: The compounds of the following Examples 32 to 92 may be obtained by referring to the synthesis methods of Examples 1 to 11. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7]

[0222] Example 93: Synthesis of Compound 93 [ka] Synthesis of compound 93: Intermediate 5-8 (40 mg, 0.089 mmol) from Example 5 was dissolved in dioxane (10 mL) and water (2 mL). 1-acetyl-5,6-dihydro-2H-pyridine-4-boronic acid pinacol ester (34 mg, 0.133 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (13 mg, 0.018 mmol), and cesium carbonate (58 mg, 0.178 mmol) were added. The reaction mixture was heated at 100°C for 4 hours. LC-MS showed no remaining raw material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol:triethylamine=100:2:1) to give compound 93 (29 mg, 0.058 mmol, 65% yield). ESI-MS: m / z 497.27 [M+H] + . 1H NMR(600MHz,DMSO-d6):δ 7.97(s,1H),7.76(s,1H),7.72-7.71(m,2H),7.62-7.56(m,2H),7.06(d,J=96.0Hz,1H),5.60-5.55(m,1H),4.16-4. 10(m,2H),4.03-3.90(m,4H),3.66-3.62(m,2H),2.51(s,3H),2.27(s,3H),2.08-2.04(m,2H),1.57(d,J=6.6Hz,3H).

[0223] Examples 94 to 108: The compounds of Examples 94 to 108 below may be obtained by referring to the synthesis method of Example 93. [Table 4-1] [Table 4-2] [Table 4-3]

[0224] Example 109: Synthesis of Compound 109 [ka] Intermediate 5-8 (40 mg, 0.089 mmol) from Example 5 was dissolved in dioxane (10 mL) and water (2 mL). 1-(methyl-d3)-pyridin-2-one-4-boronic acid pinacol ester (32 mg, 0.133 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (13 mg, 0.018 mmol), and cesium carbonate (58 mg, 0.178 mmol) were added. The reaction mixture was heated at 100 °C for 4 hours. LC-MS showed no remaining starting material. The solvent was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 2) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue was purified by thin layer chromatography (dichloromethane:methanol:triethylamine=100:2:1) to give compound 109 (25 mg, 0.051 mmol, 57% yield). ESI-MS: m / z 484.24 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 8.29(s,1H),8.22(d,J=7.2Hz,1H),7.77(s,1H),7.76-7.68(m,2H),7.65-7.54(m,2H),7.28(s,1H) ),6.86(d,J=7.0Hz,1H),5.65-5.53(m,1H),4.22-3.87(m,4H),2.29(s,3H),1.59(d,J=7.0Hz,3H).

[0225] Examples 110-121: The compounds of Examples 110 to 121 below may be obtained by referring to the synthesis method of Example 93. [Table 5-1] [Table 5-2] [Table 5-3]

[0226] Example 122: Synthesis of Compound 122 [ka] Synthesis of intermediate 122-1: 7-1 (99 mg, 0.22 mmol) was dissolved in dioxane (30 mL), followed by the addition of N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (84 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol), and cesium carbonate (143 mg, 0.44 mmol). The whole system was stirred at 100 °C for 3 h. After TLC showed no remaining raw material, 50 mL of water was added to the reaction solution, followed by extraction with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by column chromatography (dichloromethane:methanol = 60:1 to 20:1) to give 122-1 (100 mg, 82% yield). ESI-MS: m / z 555.19 [M+H] + .

[0227] Synthesis of intermediate 122-2: 122-1 (100 mg, 0.18 mmol) was dissolved in 4 M hydrochloric acid-ethyl acetate solution (10 mL) and stirred at room temperature for 2 hours. When no starting material remained as monitored by TLC, the solvent was removed under reduced pressure to give residue 122-2, which was directly used in the next step. ESI-MS: m / z 455.18 [M+H] + .

[0228] Synthesis of compound 122: 122-2 was dissolved in dichloromethane (10 mL), followed by the addition of triethylamine (36 mg, 0.36 mmol) and methanesulfonyl chloride (25 mg, 0.22 mmol). The mixture was stirred at room temperature for 2 hours. After TLC showed no remaining starting material, the reaction mixture was quenched with water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The resulting mixture was purified by column chromatography (dichloromethane:methanol = 60:1 to 15:1) to give compound 122 (50 mg, 52% yield). ESI-MS: m / z 533.20 [M+H] + . 1 H NMR(600MHz,DMSO-d6):δ 8.00(s,1H),7.80(s,1H),7.64(dd,J=7.2Hz,J=7.2Hz,1H),7.50(dd,J=7.2Hz,J=7.2Hz,1H),7.32-7.30(m,1H),7.24(t,J=54.0Hz,1H),7 .11(s,1H),5.75-5.70(m,1H),4.00-3.88(m,6H),3.40-3.37(m,2H),2.95(s,3H),2.72-2.63(m,2H),2.24(s,3H),1.56(d,J=6.6Hz,3H).

[0229] Examples 123 and 124: The compounds of Examples 123 and 124 below may be obtained by referring to the synthesis method of Example 93. [Table 6]

[0230] Example 125: Synthesis of Compound 125 [ka] Compound 124 (100 mg, 0.18 mmol) was dissolved in dichloromethane / isopropanol (22 mL, V1:V2 = 1:10) and phenylsilane (19.5 mg, 0.18 mmol) and tris(2,2,6,6-tetramethyl-3,5-heptanedionato)manganese(III) (7.6 mg, 0.01 mmol) were added at room temperature. The reaction mixture was exchanged under an oxygen atmosphere three times and then stirred at room temperature for 16 hours under an oxygen balloon atmosphere. LC-MS analysis indicated complete reaction of the starting material. The reaction mixture was filtered to obtain the filtrate, which was then concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (dichloromethane:methanol = 60:1 to 15:1) to obtain compound 125 (28 mg, 28% yield). ESI-MS: m / z 559.24 [M+H] + . 1 H NMR(400MHz,CD3OD):δ 8.32(d,J=16.0Hz,1H),7.57(t,J=7.2Hz,1H),7.47(t,J=7.2Hz,1H),7.23(t,J=8.0Hz,1H),6.99(t,J=54.8Hz,1H),5.82-5.73(m,1H), 4.56-4.24(m,4H),4.10(t,J=10.0Hz,2H),3.85-3.45(m,2H),2.39(s,3H),2.10-2.06(m,4H),1.64(d,J=7.2Hz,3H),1.28-1.24(m,4H).

[0231] Biological activity measurement tests: 1. K-Ras G12D Analysis of binding between hSOS1 and This assay examines the inhibitory effect of compounds on the protein-protein interaction between SOS1 and KRAS G12D. Homogeneous time-resolved fluorescence (HTRF) was used to measure the activity of GST-KRas bound to anti-GSK-Europium (FRET donor). G12D The binding of His-tagged hSOS1 (FRET donor) conjugated with anti-6His-XL665 was detected to identify K-Ras. G12D and measure the inhibitory effect of the compound on hSOS1.

[0232] 1.1 Reagents Buffer (5 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM EDTA, 1 mM DTT, 0.05% BAS (pH 7.0), 0.0025% lgepal, 100 mM KF) GST-tagged hK-RasG12D (self-made) His-tagged hSOS1 (self-made)

[0233] Preparation of Ras mixture: GST-hK-RasG12D 10 nM (final concentration) and anti-GSK-Europium 2 nM (final concentration) were mixed in the test buffer and allowed to stand at room temperature before use.

[0234] Preparation of SOS mixture: His-tagged hSOS1 20 nM (final concentration) and anti-6His-XL665 10 nM (final concentration) were mixed in the test buffer and allowed to stand at room temperature ready for use.

[0235] Test compounds were dissolved in DMSO at a concentration 100x the test concentration, and 50 nL was removed into a black detection microplate using a Hummingbird liquidhandler or Echo acoustic system.

[0236] 1.2 Test steps All test steps were performed at 20°C. During the test, 2.5 μL of Ras mixture was added to all wells of the detection plate using a Multidrop dispenser. After a 2-minute incubation, 2.5 μL of SOS mixture was added to all control wells except for the outer wells, to which 2.5 μL of compound control solution was added. After a 60-minute incubation, the wells were passed through the HTRF module of the Pheraster (excitation 337 nm, emission 1: 620 nm, emission 2: 665 nm).

[0237] 1.3 Data Calculation A four-parameter logistic regression model was used to evaluate IC50 The values ​​were calculated and analyzed.

[0238] 1.4 SOS1 inhibitory activity results Representative compounds of the Examples were tested according to the above method, and the SOS1 inhibitory activity data are shown in the table below. [Table 7]

[0239] where A is IC 50 <10 nM, B represents 10 nM ≤ IC 50 <50 nM, and C represents 50 nM ≤ IC 50 <100 nM, and D represents 100 nM ≤ IC 50 <300nM.

[0240] 2. 3D cell proliferation inhibition test The cell proliferation inhibition test was used to detect the inhibition of compounds on SOS1-mediated proliferation and growth of tumor cell lines at the 3D cellular level in vitro, using the CellTiter-Glo® 3D detection assay.

[0241] 2.1 Reagents and Materials NCI-H358: KRAS G12C mutant non-small cell lung cancer (NSCLC) CellTiter-Glo® 3D Cell Viability Assay, Promega, G9683 RPMI 1640 medium, Gibco, A10491-01 FBS, Gibco, 10099141C

[0242] 2.2 Test steps: 2.2.1 Cell culture On day 1, NCI-H358 was passaged in T75 cell culture flasks. On day 3, the medium was removed, rinsed once with DPBS, and the cells were digested with 2 mL of TrypLE™ Express Enzyme at room temperature or 37°C until the cells detached. Five mL of fresh medium was added and the cells were centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, and 5 mL of fresh medium was added to resuspend the cells. The cells were counted and then seeded into 3D cell plates (Echo Qualified polypropylene 384-well microplate 2.0, clear, flat bottom) at 40 μL / well.

[0243] 2.2.2 3D cell growth inhibition On day 1, test compounds were dissolved in DMSO to prepare a 10 mM stock solution. After 1000-fold dilution using DMSO, a 3-fold gradient dilution was performed to obtain a 10 concentration gradient, with a starting concentration of 10 μM. 200 nL of the compound was added to the culture plate. On the 8th day, 40 μL / well of 3D CTG reagent was added, and the signal value was detected using Envision.

[0244] 2.3 Data analysis Compound IC using Graphpad Prism 8 nonlinear regression equations 50 values ​​were assigned. Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×HillSlope)) X: Log of cpd concentration (logarithm of compound concentration) Y: Percent inhibition (%inh)

[0245] 2.4 NCI-H358 cell proliferation inhibitory activity The compounds of the examples were tested by the above method, and the NCI-H358 cell proliferation inhibitory activity data were as shown in the table below. [Table 8]

[0246] where A is IC50 <50nM, B represents 50nM ≤ IC 50 <100 nM, and C represents 100 nM ≤ IC 50 <500nM.

Claims

1. A compound of formula (A), and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, [Formula 1] During the ceremony, [Case 2] represents a single bond or a double bond, Y and Z are both selected from C or N, and when Y is N, Z is C, and when Y is C, Z is N; Y and Z together with the atoms to which they are attached form a ring A, and ring A is selected from a 5- to 12-membered heterocyclyl group or a 5- to 12-membered heteroaryl group; R 2 is one, two or three, each occurrence of which independently represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a formyl group, an oxo group, C 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 Alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl) 2 , C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 Alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl) 2 , C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 the aryl group, the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group are all optionally substituted by one or more cyano groups, hydroxy groups or halogens; R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted by one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl group, C 4~12 Cycloalkenyl group, 4- to 12-membered heterocyclyl group, C 6~12 Aryl group, 5- to 12-membered heteroaryl group, C 6~12 Aryl condensation C 4~12 Cycloalkyl group, C 6~12 Aryl-fused 4- to 12-membered heterocyclyl group or C 6~12 Aryl condensation C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, a cyano group, a halogen atom, an amino group, a hydroxy group, an oxo group, a nitro group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group each optionally include a halogen, a hydroxy group, an amino group, —SO 2 -C 1~4 and optionally substituted with one or more of the following substituents: alkyl or oxo; w is 0, 1, 2, 3, or 4; [C3] is a double bond, X is selected from C and R 1 is -O-R A , -N(R D ) R B Or R C Selected from R 1 Ga-O-R A If R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D ) R B If R B is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 Alkyl) 2 Selected from R 1 R C If R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each optionally be substituted with deuterium, a hydroxyl group, a cyano group, 1~3Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; [C4] is a single bond, X is selected from N and R 1 is C 3~10 Cycloalkyl group, C 3~10 Cycloalkenyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 3~10 Cycloalkyl group, C 3~10 Cycloalkenyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R a4 and / or R b4 may be substituted by Each R a4 each independently, if present, is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R b4 and / or R c4 may be substituted by Each R b4 each independently, if present, represents -OR c4 , -NR c4 R c4 , halogen, -CN, -C(O)R c4 , -C(O)OR c4 , -C(O)NR c4 R c4, -OC(O)R c4 , -S(O) 2 R c4 , -S(O) 2 N.R. c4 R c4 , -NHC(O)R c4 , -N(C 1~4 alkyl)C(O)R c4 , -NHC(O)OR c4 or divalent substituents =O or =NH, where =O and =NH may be the only substituents on a non-aromatic ring system; Each R c4 each independently, if present, is hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R d4 and / or R e4 may be substituted by Each R d4 each independently, if present, represents -OR e4 , -NR e4 R e4 , halogen, -CN, -C(O)R e4 , -C(O)OR e4 , -C(O)NR e4 R e4 , -S(O) 2 R e4 , -S(O) 2 N.R. e4 R e4 , -NHC(O)R e4 , -N(C 1~4 alkyl)C(O)R e4or a divalent substituent =O, where =O may be the only substituent on a non-aromatic ring system, Each R e4 each independently, if present, is hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted by one or more hydrogen, cyano, hydroxyl, or halogen atoms; wherein Z and Y are included in the number of atoms or atoms of ring A; Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N or S, and the number of heteroatoms is 1, 2, 3 or 4; Optionally, the compound has a structure according to formula (A'): [C5] A compound, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, wherein each substituent of formula (A') is defined as described in formula (A).

2. A compound of formula (I), and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs or solvates, [C6] During the ceremony, [C7] represents a single bond or a double bond, Y and Z are both selected from C or N, and when Y is N, Z is C, and when Y is C, Z is N; Y and Z together with the atoms to which they are attached form a ring A, and ring A is selected from a 5- to 12-membered heterocyclyl group or a 5- to 12-membered heteroaryl group; R 2 is one, two or three, each occurrence of which independently represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a formyl group, an oxo group, C 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 Alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl) 2 , C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 1~6 Alkoxy group, -C 1~6 Alkyl-NH(C 1~6 Alkyl), -C 1~6 Alkyl-N(C 1~6 Alkyl) 2 , C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 the aryl group, the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group are all optionally substituted by one or more cyano groups, hydroxy groups or halogens; R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted by one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl group, C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 5~12 Heteroaryl group, C 6~12 Aryl condensation C 4~12 Cycloalkyl group, C 6~12 Aryl condensation C 4~12 Heterocyclyl group or C 6~12 Aryl condensation C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, a cyano group, a halogen atom, an amino group, a hydroxy group, an oxo group, a nitro group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group each optionally include a halogen, a hydroxy group, an amino group, —SO 2 -C 1~4 and optionally substituted with one or more of the following substituents: alkyl or oxo; w is 0, 1, 2, 3, or 4; [C8] is a double bond, X is selected from C and R 1 is -O-R A , -N(R D ) R B Or R C Selected from R 1 Ga-O-R A If R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D ) R B If R B is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 Alkyl) 2 Selected from R 1 R C If R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally include a hydroxy group, 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; [C9] is a single bond, X is selected from N and R 1 is C 3~10 Cycloalkyl group, C 3~10 Cycloalkenyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 3~10 Cycloalkyl group, C 3~10Cycloalkenyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R a4 and / or R b4 may be substituted by Each R a4 each independently, if present, is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R b4 and / or R c4 may be substituted by Each R b4 each independently, if present, represents -OR c4 , -NR c4 R c4 , halogen, -CN, -C(O)R c4 , -C(O)OR c4 , -C(O)NR c4 R c4 , -OC(O)R c4 , -S(O) 2 R c4 , -S(O) 2 N.R. c4 R c4 , -NHC(O)R c4 , -N(C 1~4 alkyl)C(O)R c4 , -NHC(O)OR c4 or divalent substituents =O or =NH, where =O and =NH may be the only substituents on a non-aromatic ring system; Each R c4 each independently, if present, is hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each may optionally have one or more of the same or different R d4 and / or R e4 may be substituted by Each R d4 each independently, if present, represents -OR e4 , -NR e4 R e4 , halogen, -CN, -C(O)R e4 , -C(O)OR e4 , -C(O)NR e4 R e4 , -S(O) 2 R e4 , -S(O) 2 N.R. e4 R e4 , -NHC(O)R e4 , -N(C 1~4 alkyl)C(O)R e4 or a divalent substituent =O, where =O may be the only substituent on a non-aromatic ring system, Each R e4 each independently, if present, is hydrogen, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group may each be optionally substituted by one or more hydrogen, cyano, hydroxyl, or halogen atoms; wherein Z and Y are included in the number of atoms or atoms of ring A; Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N or S, and the number of heteroatoms is 1, 2, 3 or 4; Optionally, the compound has a structure according to Formula (II), (III) or (IV): [C10] [C11] [C12] Compounds, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs or solvates thereof, wherein each substituent of formula (II), formula (III) or formula (IV) is defined as described in formula (I).

3. In some cases, [C13] is a double bond, X is selected from C and R 1 is -O-R A and R A is C 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 Alkyl) 2 Selected from Or, R A is C 3~6 Cycloalkyl group, C 6~10 aryl group, 3- to 6-membered heterocyclyl group, or 5- to 6-membered heteroaryl group, 3~6 Cycloalkyl group, C 6~10 The aryl group, the 3- to 6-membered heterocyclyl group, and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R A is selected from a 5- to 6-membered heterocyclyl group or a 5- to 6-membered heteroaryl group, wherein the 5- to 6-membered heterocyclyl group and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4Alkyl group or -COC 1~4 selected from alkyl groups, Or, R A is selected from a 5- to 6-membered heterocyclyl group, wherein said 5- to 6-membered heterocyclyl group optionally has one to two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R A is selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein said 5- to 6-membered monocyclic heterocyclyl groups optionally have one to two identical or different R a1 each heteroatom in the 5- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R A is selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally have one or two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R A is the following functional group: [C14] Selected from In some cases, [C15] is a double bond, X is selected from C and R 1 is -N(R D ) R B and R B is C 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R B is C 1~6 an alkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 The alkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R B is C 1~6alkyl group or a 5- to 6-membered monocyclic heterocyclyl group, 1~6 The alkyl group and the 5- to 6-membered monocyclic heterocyclyl group each optionally have one or two identical or different R b1 each heteroatom in said 5- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R b1 each independently, when present, represents a halogen atom, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group or -COC 1~4 selected from alkyl groups, Or, R B is selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein each of the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group may optionally have one to two identical or different R b1 may be substituted by Each R b1 each, if present, is independently selected from oxo, formyl, acetyl, methyl, ethyl, methoxy, and ethoxy; Or, R B is the following functional group: [C16] Selected from R D is hydrogen, C 1~6 Alkyl group or -OC 1~6 alkyl groups, or R D is hydrogen or C 1~3 alkyl groups, or R D is selected from hydrogen or a methyl group, or R D is selected from hydrogen, In some cases, [C17] is a double bond, X is selected from C and R 1 is R C and R C is C 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 cycloalkyl group or 3- to 10-membered heterocyclyl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 The cycloalkyl group and the 3- to 10-membered heterocyclyl group each optionally include a hydroxy group, 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; Or, R C is C 1~6 Alkyl group, C 3~10 cycloalkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 The cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 , -CH 2 CONHC 1~4 alkyl group or 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 , -CH 2 CONHC 1~4each of the alkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted by one or more substituents selected from hydroxy, methyl, methoxy or halogen; Or, R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 or a 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 and each of the 3- to 6-membered heterocyclyl groups may be optionally substituted by one or more substituents selected from hydroxy, methyl, methoxy or halogen; Or, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, and a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1each independently, when present, is a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, an acetyl group, a propionyl group, a methoxy group, an ethoxy group, a methyl group, a ethyl group, a n-propyl group, an isopropyl group, a -CH 2 CON (CH 3 ) 2 or a 6-membered heterocyclyl group, wherein the acetyl group, the propionyl group, the methoxy group, the ethoxy group, the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the -CH 2 CON (CH 3 ) 2 and each of the 6-membered heterocyclyl groups may be optionally substituted by one or more substituents selected from hydroxy, methyl, methoxy or halogen; Or, R C is selected from a 6-membered monocyclic heterocyclyl group, a 4 / 6 spiroheterocyclyl group, a 4 / 4 spiroheterocyclyl group, a 7-membered bridged heterocyclyl group, and a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4 / 6 spiroheterocyclyl group, the 4 / 4 spiroheterocyclyl group, the 7-membered bridged heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally have 1 to 3 identical or different R c1 may be substituted by Each R c1 each independently, when present, is a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, an acetyl group, -COCH 2 CH 3 , -COCH 2 OH, hydroxymethyl group, hydroxyethyl group, -CH 2 OCH 3 , methoxy group, ethoxy group, methyl group, ethyl group, n-propyl group, isopropyl group, -CH 2 CON (CH 3 ) 2 and a 6-membered heterocyclyl group; Or, R C teeth, [C18] wherein R CEach of them may optionally have one or two identical or different R c1 may be substituted by Each R c1 each independently, when present, is F, Cl, Br, a hydroxy group, a cyano group, an amino group, an oxo group, an acetyl group, -COCH 2 CH 3 , -COCH 2 OH, hydroxymethyl group, hydroxyethyl group, -CH 2 OCH 3 , methoxy group, methyl group, ethyl group, isopropyl group, -CH 2 CON (CH 3 ) 2 and a morpholinyl group; Or, optionally, R c1 R may be substituted by C is the following functional group: [C19] 2. The compound according to claim 1, and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, characterized in that it is selected from the group consisting of:

4. Ring A is selected from a 5- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the heteroatoms in the 5- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group are each independently selected from O or N, and the number of heteroatoms is 1 to 4; Alternatively, Ring A is selected from a 5-membered monocyclic heterocyclyl group, a 6-membered monocyclic heterocyclyl group, a 5-membered monocyclic heteroaryl group, a 6-membered monocyclic heteroaryl group, a 5 / 5-membered fused heterocyclyl group, a 5 / 4-membered fused heterocyclyl group, a 5 / 6-membered fused heterocyclyl group, a 6 / 5-membered fused heterocyclyl group, a 6 / 4-membered fused heterocyclyl group, a 6 / 6-membered fused heterocyclyl group, a 5 / 3-membered spiroheterocyclyl group, a 5 / 5-membered spiroheterocyclyl group, a 5 / 4-membered spiroheterocyclyl group, a 5 / 6-membered spiroheterocyclyl group, a 6 / 3-membered spiroheterocyclyl group, a 6 / 5-membered spiroheterocyclyl group, a 6 / 4-membered spiroheterocyclyl group, or a 6 / 6-membered spiroheterocyclyl group, heteroatoms in the aryl group, 6-membered monocyclic heterocyclyl group, 5-membered monocyclic heteroaryl group, 6-membered monocyclic heteroaryl group, 5 / 5-membered fused heterocyclyl group, 5 / 4-membered fused heterocyclyl group, 5 / 6-membered fused heterocyclyl group, 6 / 5-membered fused heterocyclyl group, 6 / 4-membered fused heterocyclyl group, 6 / 6-membered fused heterocyclyl group, 5 / 3-membered spiro heterocyclyl group, 5 / 5-membered spiro heterocyclyl group, 5 / 4-membered spiro heterocyclyl group, 5 / 6-membered spiro heterocyclyl group, 6 / 3-membered spiro heterocyclyl group, 6 / 5-membered spiro heterocyclyl group, 6 / 4-membered spiro heterocyclyl group and 6 / 6-membered spiro heterocyclyl group are each independently selected from N, the number of heteroatoms is 1 to 4, or ring A is selected from a 5-membered monocyclic heterocyclyl group, a 6-membered monocyclic heterocyclyl group, a 5-membered monocyclic heteroaryl group, a 6-membered monocyclic heteroaryl group, a 5 / 5-membered fused heterocyclyl group, a 5 / 6-membered fused heterocyclyl group, or a 5 / 3-membered spiroheterocyclyl group, wherein the heteroatoms in the 5-membered monocyclic heterocyclyl group, the 6-membered monocyclic heterocyclyl group, the 5-membered monocyclic heteroaryl group, the 6-membered monocyclic heteroaryl group, the 5 / 5-membered fused heterocyclyl group, the 5 / 6-membered fused heterocyclyl group, and the 5 / 3-membered spiroheterocyclyl group are each independently selected from N, and the number of heteroatoms is 1 to 3; Alternatively, ring A is selected from a 5-membered monocyclic heterocyclyl group or a 5-membered monocyclic heteroaryl group, the heteroatoms in said 5-membered monocyclic heterocyclyl group and 5-membered monocyclic heteroaryl group are selected from N, and the number of heteroatoms is 1 to 3; Alternatively, Ring A is a functional group: [C20] Selected from Alternatively, Ring A is a functional group: [C21] 2. The compound according to claim 1, and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, characterized in that it is selected from the group consisting of:

5. R 2 is one, two or three, each occurrence of which independently represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a formyl group, an oxo group, C 1~3 Alkyl group, C 1~3 Alkoxy group, -C 1~3 Alkyl-NH(C 1~3 alkyl) or -C 1~3 Alkyl-N(C 1~3 Alkyl) 2 wherein said C 1~3 Alkyl group, C 1~3 Alkoxy group, -C 1~3 Alkyl-NH(C 1~3 alkyl) and -C 1~3 Alkyl-N(C 1~3 Alkyl) 2 each of which may be optionally substituted with one or more hydroxy groups or halogens; Or, R 2 is one, two or three and each occurrence is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, methoxy, methyl, ethyl, n-propyl or isopropyl; Or, R 2is one or two and each occurrence is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, methoxy, or methyl; Or, R 2 is one or two, each occurrence of which is independently selected from hydrogen or a methyl group, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

6. R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, C 1~4 Alkyl group, C 1~4 Alkoxy group or C 3~6 cycloalkyl groups, wherein said C 1~4 Alkyl group, C 1~4 Alkoxy group and C 3~6 Any cycloalkyl group may be optionally substituted with one or more hydroxy groups or halogens; Or, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a methoxy group; Or, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and a cyclopropyl group; Or, R 3 is selected from hydrogen, F, Cl, Br, an amino group, a methyl group, an ethyl group, or a cyclopropyl group, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof.

7. Ring B is C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 6~8 Aryl condensation C 4~6 Cycloalkyl group, C 6~8 Aryl condensation C 4~6 Heterocyclyl group or C 5~12 Heteroaryl groups are selected from Alternatively, ring B is C 6~10 Aryl group or C 5~10 Heteroaryl groups are selected from Alternatively, the compound according to claim 1, characterized in that ring B is selected from a phenyl group or a pyridinyl group, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

8. Each R 4 When present, each independently represents a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl group, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl group, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group each optionally include a halogen, a hydroxy group, an amino group, —SO 2 -C 1~4 and optionally substituted with one or more of the following substituents: alkyl or oxo; w is 0, 1, 2, or 3; Or, each R 4 are each independently a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, 1~4 Alkyl group, C 1~4 Haloalkyl group or C 1~4 hydroxyalkyl groups, wherein the C 1~4 Alkyl group, C 1~4 Haloalkyl group and C 1~4 any hydroxyalkyl group may be optionally substituted with one or more of the following substituents: halogen, hydroxy, or amino; w is 1, 2, or 3; Or, each R 4 are each independently selected from hydrogen, cyano, halogen, amino, nitro, methyl, ethyl, n-propyl, or isopropyl, each of which may be optionally substituted with one or more of the following substituents: halogen or hydroxy; w is 1, 2, or 3; Or, each R 4 are each independently selected from hydrogen, halogen, amino, methyl, ethyl, or isopropyl, each of which may be optionally substituted with one or more of the following substituents: halogen or hydroxy; w is 1, 2, or 3; Or, each R 4 each independently represents a hydrogen atom, a halogen atom, an amino group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, or -CF 2 CH 2 OH, -C(CH 3 ) 2 OH or -CF 2 CH 3 and w is 1, 2 or 3, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

9. A compound of formula (B), and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, [C22] In the formula, R 1 is -O-R A , -N(R D ) R B Or R C Selected from R 1 Ga-O-R A If R A is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R 1 -N(R D ) R B If R B is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 an aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group; R D is a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 Alkyl) 2 Selected from R 1 R C If R C is C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally include a deuterium atom, a hydroxyl group, a cyano group, a C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; R 2 is one or two, and each occurrence independently represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a formyl group, an oxo group, C 1~6 Alkyl group, C 1~6 Alkoxy group, haloC 1~6 Alkyl group or haloC 1~6 selected from alkoxy groups, R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, C 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 Both the cycloalkyl group and the 3- to 6-membered heterocyclyl group may be optionally substituted by one or more hydroxy groups or halogens; Ring B is C 4~12 Cycloalkyl group, C 4~12 Cycloalkenyl group, C 4~12 Heterocyclyl group, C 6~12 Aryl group, C 5~12 Heteroaryl group, C 6~12 Aryl condensation C 4~12 Cycloalkyl group, C 6~12 Aryl condensation C 4~12 Heterocyclyl group or C 6~12 Aryl condensation C 4~12 cycloalkenyl groups, Each R 4 When present, each independently represents hydrogen, a cyano group, a halogen atom, an amino group, a hydroxy group, an oxo group, a nitro group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, C 1~6 Haloalkyl group, C 1~6 Hydroxyalkyl group, C 1~6 Alkoxy group, -C 0~6 Alkyl-NH-C 1~6 Alkyl group, -C 0~6 Alkyl-N(C 1~6 Alkyl) (C 1~6 Alkyl), C 3~6 Cycloalkyl group, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group each optionally include a halogen, a hydroxy group, an amino group, —SO 2 -C 1~4 and optionally substituted with one or more of the following substituents: alkyl or oxo; w is 0, 1, 2, 3, or 4; Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N or S, and the number of heteroatoms is 1, 2, 3 or 4; Optionally, the compound has a structure according to formula (C): [C23] Compounds, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, wherein each substituent of formula (C) is defined as described in formula (B).

10. R 1 is -O-R A If R A is C 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, C 2~6 Alkenyl group, C 2~6 Alkynyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group or -N(C 1~6 Alkyl) 2Selected from Or, R A is C 3~6 Cycloalkyl group, C 6~10 aryl group, 3- to 6-membered heterocyclyl group, or 5- to 6-membered heteroaryl group, 3~6 Cycloalkyl group, C 6~10 The aryl group, the 3- to 6-membered heterocyclyl group, and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R A is selected from a 5- to 6-membered heterocyclyl group or a 5- to 6-membered heteroaryl group, wherein the 5- to 6-membered heterocyclyl group and the 5- to 6-membered heteroaryl group each optionally have 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group or -COC 1~4 selected from alkyl groups, Or, R A is selected from a 5- to 6-membered heterocyclyl group, wherein said 5- to 6-membered heterocyclyl group optionally has one to two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R Ais selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein said 5- to 6-membered monocyclic heterocyclyl groups optionally have one to two identical or different R a1 each heteroatom in said 5- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R A is selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally have one or two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from halogen, oxo, formyl, acetyl, methyl, ethyl, n-propyl, isopropyl, or methoxy; Or, R A is the following functional group: [C24] Selected from R 1 is -N(R D ) R B If R B is C 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 Alkyl group, C 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R B is C 1~6 an alkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 1~6 The alkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R B is C 1~6 alkyl group or a 5- to 6-membered monocyclic heterocyclyl group, 1~6 The alkyl group and the 5- to 6-membered monocyclic heterocyclyl group each optionally have one or two identical or different R b1 each heteroatom in the 5- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R b1 each independently, when present, represents a halogen atom, an oxo group, a formyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group or -COC 1~4 selected from alkyl groups, Or, R Bis selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein each of the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group may optionally have one to two identical or different R b1 may be substituted by Each R b1 each, if present, is independently selected from oxo, formyl, acetyl, methyl, ethyl, methoxy, and ethoxy; Or, R B is the following functional group: [C25] Selected from R D is hydrogen, C 1~6 Alkyl group or -OC 1~6 alkyl groups, or R D is hydrogen or C 1~3 alkyl groups, or R D is selected from hydrogen or a methyl group, or R D is selected from hydrogen, R 1 is R C If R C is C 3~10 Cycloalkyl group, C 6~10 aryl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 3~10 Cycloalkyl group, C 6~10 The aryl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 cycloalkyl group or 3- to 10-membered heterocyclyl group, 1~6 Alkyl group, -OC 1~6 Alkyl group, -SC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~6 Alkyl group, -CH 2 CON (C 1~6 Alkyl) 2 , -CH 2 CONHC 1~6 Alkyl group, -NHC 1~6 Alkyl group, -N(C 1~6 Alkyl) 2 , C 3~10 The cycloalkyl group and the 3- to 10-membered heterocyclyl group are each optionally substituted with deuterium, a hydroxyl group, a cyano group, a C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; Or, R C is C 3~10 cycloalkyl group, a 3- to 10-membered heterocyclyl group, or a 5- to 10-membered heteroaryl group, 3~10 The cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a nitro group, an oxo group, a formyl group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 , -CH 2 CONHC 1~4 Alkyl group, C 3~6 cycloalkyl group or 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, -OC 1~4 Alkyl group, -SC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 COC 1~4 Alkyl group, -CH 2 CON (C 1~4 Alkyl) 2 , -CH 2 CONHC 1~4 Alkyl group, C 3~6 The cycloalkyl group and the 3- to 6-membered heterocyclyl group are each optionally substituted with deuterium, a hydroxyl group, a cyano group, a C 1~3 Alkyl group, C 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; Or, R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~4 Alkyl) 2 or a 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~4 Alkyl) 2 and each of the 3- to 6-membered heterocyclyl groups is optionally substituted with one or more substituents selected from deuterium, hydroxyl, cyano, methyl, methoxy, or halogen; Or, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, an 8- to 10-membered fused heterocyclyl group, or a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, the 8- to 10-membered fused heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally comprises 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, is a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, an acetyl group, a propionyl group, a methanesulfonyl group, a methoxy group, an ethoxy group, a methyl group, a ethyl group, a n-propyl group, an isopropyl group, a -CH 2 CON (CH 3 ) 2 , —CO-cyclopropyl, —CO-cyclobutyl, 4-membered heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl, wherein the acetyl group, propionyl group, methanesulfonyl group, methoxy group, ethoxy group, methyl group, ethyl group, n-propyl group, isopropyl group, —CH 2 CON (CH 3 ) 2 , -CO-cyclopropyl, -CO-cyclobutyl, 4-membered heterocyclyl, 5-membered heterocyclyl and 6-membered heterocyclyl groups may each be optionally substituted by one or more substituents selected from deuterium, hydroxyl, cyano, methyl, methoxy or halogen; Or, R C is selected from a 6-membered monocyclic heterocyclyl group, a 4-membered / 6-membered spiroheterocyclyl group, a 4-membered / 4-membered spiroheterocyclyl group, a 6-membered / 5-membered fused heterocyclyl group, a 7-membered bridged heterocyclyl group, or a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4-membered / 6-membered spiroheterocyclyl group, the 4-membered / 4-membered spiroheterocyclyl group, the 6-membered / 4-membered fused heterocyclyl group, the 7-membered bridged heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, is a halogen, a hydroxyl group, a cyano group, an amino group, an oxo group, a formyl group, an acetyl group, a propionyl group, a methanesulfonyl group, a methoxy group, an ethoxy group, a methyl group, a ethyl group, a n-propyl group, an isopropyl group, a -CH 2 CON (CH 3 ) 2 , —CO-cyclopropyl, 4-membered heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl, wherein the acetyl group, propionyl group, methanesulfonyl group, methoxy group, ethoxy group, methyl group, ethyl group, n-propyl group, isopropyl group, —CH 2 CON (CH 3 ) 2 , -CO-cyclopropyl, 4-membered heterocyclyl, 5-membered heterocyclyl and 6-membered heterocyclyl groups are each optionally substituted by one or more substituents selected from deuterium, hydroxyl, cyano, methyl, methoxy or halogen; Or, R C teeth, [C26] wherein R C Each of them may optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, is F, Cl, Br, a hydroxy group, a cyano group, an amino group, an oxo group, a methanesulfonyl group, an acetyl group, -COCH 2 CH 3 , -COCH 2 OH, -COCH 2 CN, -CH(OH)(CH 3 ) 2 , hydroxymethyl group, hydroxyethyl group, -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , methoxy group, methyl group, CD 3 , an ethyl group, an isopropyl group, a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoroethyl group, a difluoroethyl group, a trifluoroethyl group, [C27] , -CH 2 CON (CH 3 ) 2 or a morpholinyl group, Or, optionally, R c1 R may be substituted by C is the following functional group: [C28] 10. The compound according to claim 9, and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, characterized in that it is selected from the group consisting of:

11. R 2 is one or two and each occurrence is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, oxo, methoxy, methyl, ethyl, n-propyl, and isopropyl; Or, R 2is one or two and each occurrence is independently selected from hydrogen, halogen, hydroxy, cyano, amino, nitro, methoxy, or methyl; Or, R 2 is one or two and each occurrence is independently selected from hydrogen or a methyl group; Or, R 2 is hydrogen, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

12. R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a methoxy group; Or, R 3 is selected from hydrogen, halogen, a hydroxy group, an amino group, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and a cyclopropyl group; Or, R 3 is selected from hydrogen, F, Cl, Br, an amino group, a methyl group, an ethyl group, or a cyclopropyl group, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof.

13. Ring B is C 4~12 Cycloalkenyl group, 4- to 12-membered heterocyclyl group, C 6~12 Aryl group, C 6~8 Aryl condensation C 4~6 Cycloalkyl group, C 6~8 an aryl-fused 4- to 6-membered heterocyclyl group or a 5- to 12-membered heteroaryl group; Alternatively, ring B is C 6~10 an aryl group, a 5- to 10-membered heteroaryl group, or C 6~8 aryl-fused 4- to 6-membered heterocyclyl groups; Alternatively, the compound according to claim 9, characterized in that ring B is selected from a phenyl group, a pyridinyl group, or a benzotetrahydrofuryl group, and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives.

14. Each R 4 When present, each independently represents a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, C 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl group, C 3~6 halocycloalkyl group or 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, C 1~4 Haloalkyl group, C 1~4 Hydroxyalkyl group, C 3~6 Cycloalkyl group, C 3~6 The halocycloalkyl group and the 3- to 6-membered heterocyclyl group each optionally include a halogen, a hydroxy group, an amino group, —SO 2 -C 1~4 and optionally substituted with one or more of the following substituents: alkyl or oxo; w is 0, 1, 2, or 3; Or, each R 4 are each independently a hydrogen atom, a cyano group, a halogen atom, an amino group, a nitro group, 1~4 Alkyl group, C 1~4 Haloalkyl group or C 1~4 hydroxyalkyl groups, wherein the C 1~4 Alkyl group, C 1~4 Haloalkyl group and C 1~4 any hydroxyalkyl group may be optionally substituted with one or more of the following substituents: halogen, hydroxy, or amino; w is 1, 2, or 3; Or, each R 4are each independently selected from hydrogen, cyano, halogen, amino, nitro, methyl, ethyl, n-propyl, or isopropyl, each of which may be optionally substituted with one or more of the following substituents: halogen or hydroxy; w is 1, 2, or 3; Or, each R 4 are each independently selected from hydrogen, halogen, amino, cyano, methyl, ethyl, or isopropyl, each of which may be optionally substituted with one or more of the following substituents: halogen or hydroxy; w is 1, 2, or 3; Or, each R 4 each independently represents a hydrogen atom, a fluorine atom, an amino group, a cyano group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, or -CF 2 CH 2 OH, -C(CH 3 ) 2 OH, -CF 2 CH 3 or -CH 2 CHF 2 and w is 1, 2 or 3, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

15. A compound of formula (D), and its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, [C29] In the formula, each R 4 each independently represents a cyano group, a halogen, an amino group, 1~6 Alkyl group or C 1~6 haloalkyl groups, wherein said C 1~6 Alkyl group and C 1~6 Any haloalkyl group may be optionally substituted with one or more hydroxy groups; w is 1 or 2; R 1is -O-R A , -N(R D ) R B Or R C Selected from R 1 Ga-O-R A If R A is selected from a 3- to 10-membered heterocyclyl group, wherein said 3- to 10-membered heterocyclyl group optionally has 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, if present, is C 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, R 1 -N(R D ) R B If R B is C 1~6 alkyl group or 3- to 10-membered heterocyclyl group, 1~6 The alkyl group and the 3- to 10-membered heterocyclyl group each optionally have 1 to 3 identical or different R b1 may be substituted by Each R b1 each independently, if present, represents -OC 1~6 selected from alkyl groups, R D is selected from hydrogen, R 1 R C If R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a methanesulfonyl group, C 1~6 Alkyl group, -OC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~6 Alkyl) 2 or a 3- to 10-membered heterocyclyl group, 1~6 Alkyl group, -OC 1~6 Alkyl group, -COC 1~6 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~6 Alkyl) 2 and the 3- to 10-membered heterocyclyl group may each optionally be substituted with deuterium, a hydroxyl group, a cyano group, 1~3 may be substituted by one or more substituents selected from an alkoxy group or a halogen; Unless otherwise specified, the heteroatoms in the above heteroaryl and heterocyclyl groups are each independently selected from O, N or S, and the number of heteroatoms is 1, 2, 3 or 4; In some cases, R 1 is -O-R A If R A is selected from a 3- to 6-membered heterocyclyl group, wherein said 3- to 6-membered heterocyclyl group optionally has 1 to 3 identical or different R a1 may be substituted by Each R a1 each independently, if present, is C 1~6 Alkyl group or -COC 1~6 selected from alkyl groups, Or, R A is selected from a 5- to 6-membered heterocyclyl group, wherein said 5- to 6-membered heterocyclyl group optionally has one to two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from acetyl, methyl, ethyl, n-propyl, or isopropyl; Or, R A is selected from 5- to 6-membered monocyclic heterocyclyl groups, wherein said 5- to 6-membered monocyclic heterocyclyl groups optionally have one to two identical or different R a1each heteroatom in said 5- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R a1 each, if present, is independently selected from an acetyl group, a methyl group, or an ethyl group; Or, R A is selected from a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, and each of the tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, piperidinyl group, tetrahydropyranyl group, and tetrahydrothiopyranyl group may optionally have one or two identical or different R a1 may be substituted by Each R a1 each, if present, is independently selected from an acetyl group, a methyl group, or an ethyl group; Or, R A is the following functional group: [C30] Selected from R 1 is -N(R D ) R B If R B is C 1~6 an alkyl group or a 3- to 6-membered monocyclic heterocyclyl group, 1~6 Each of the alkyl group and the 3- to 6-membered monocyclic heterocyclyl group may optionally have one or two identical or different R b1 each heteroatom in said 3- to 6-membered monocyclic heterocyclyl group is independently selected from O, N or S, and the number of heteroatoms is 1; Each R b1 each independently, if present, represents -OC 1~4 selected from alkyl groups, Or, R Bis selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an oxetanyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyranyl group, and a tetrahydrothiopyranyl group, wherein each of the methyl group, the ethyl group, the n-propyl group, the isopropyl group, the oxetanyl group, the tetrahydrofuryl group, the tetrahydrothienyl group, the pyrrolidinyl group, the piperidinyl group, the tetrahydropyranyl group, and the tetrahydrothiopyranyl group may optionally have one to two identical or different R b1 may be substituted by Each R b1 are each independently selected from a methoxy group or an ethoxy group, if present; Or, R B is the following functional group: [C31] Selected from R D is hydrogen, C 1~6 Alkyl group or -OC 1~6 alkyl groups, or R D is hydrogen or C 1~3 alkyl groups, or R D is selected from hydrogen or a methyl group, or R D is selected from hydrogen, R 1 is R C If R C is selected from a 3- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, wherein the 3- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, represents a halogen, a hydroxyl group, a cyano group, an amino group, a methanesulfonyl group, C 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~4 Alkyl) 2 or a 3- to 6-membered heterocyclyl group, 1~4 Alkyl group, -OC 1~4 Alkyl group, -COC 1~4 Alkyl group, -COC 3~6 Cycloalkyl group, -CH 2 CON (C 1~4 Alkyl) 2 and each of the 3- to 6-membered heterocyclyl groups is optionally substituted with one or more substituents selected from deuterium, hydroxyl, cyano, methoxy, or halogen; Or, R C is selected from a 5- to 6-membered monocyclic heterocyclyl group, a 6- to 10-membered spiroheterocyclyl group, a 6- to 8-membered bridged heterocyclyl group, an 8- to 10-membered fused heterocyclyl group, or a 5- to 6-membered monocyclic heteroaryl group, wherein the 5- to 6-membered monocyclic heterocyclyl group, the 6- to 10-membered spiroheterocyclyl group, the 6- to 8-membered bridged heterocyclyl group, the 8- to 10-membered fused heterocyclyl group, and the 5- to 6-membered monocyclic heteroaryl group each optionally comprises 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, if present, is a halogen, a hydroxyl group, a cyano group, an amino group, a methanesulfonyl group, a methyl group, a ethyl group, a n-propyl group, a isopropyl group, a methoxy group, a ethoxy group, a acetyl group, a propionyl group, a -CO-cyclopropyl group, a -CO-cyclobutyl group, a -CH 2 CON (CH 3 ) 2 , 4-membered heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl, wherein the methanesulfonyl group, methyl group, ethyl group, n-propyl group, isopropyl group, methoxy group, ethoxy group, acetyl group, propionyl group, -CO-cyclopropyl group, -CO-cyclobutyl group, -CH 2 CON (CH 3 ) 2 , the 4-membered heterocyclyl group, the 5-membered heterocyclyl group and the 6-membered heterocyclyl group are all optionally substituted by one or more substituents selected from deuterium, hydroxyl, cyano, methoxy or halogen; Or, R C is selected from a 6-membered monocyclic heterocyclyl group, a 4-membered / 6-membered spiroheterocyclyl group, a 4-membered / 4-membered spiroheterocyclyl group, a 7-membered bridged heterocyclyl group, a 6-membered / 5-membered fused heterocyclyl group, or a 6-membered monocyclic heteroaryl group, wherein the 6-membered monocyclic heterocyclyl group, the 4-membered / 6-membered spiroheterocyclyl group, the 4-membered / 4-membered spiroheterocyclyl group, the 7-membered bridged heterocyclyl group, the 6-membered / 4-membered fused heterocyclyl group, and the 6-membered monocyclic heteroaryl group each optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, if present, is a halogen, a hydroxyl group, a cyano group, an amino group, a methanesulfonyl group, a methyl group, a ethyl group, a n-propyl group, a isopropyl group, a methoxy group, a ethoxy group, a acetyl group, a propionyl group, a -CO-cyclopropyl group, a -CH 2 CON (CH 3 ) 2 , a 4-membered heterocyclyl group, a 5-membered heterocyclyl group or a 6-membered heterocyclyl group, wherein said methanesulfonyl group, methyl group, ethyl group, n-propyl group, isopropyl group, methoxy group, ethoxy group, acetyl group, propionyl group, -CO-cyclopropyl group, the 4-membered heterocyclyl group, the 5-membered heterocyclyl group and the 6-membered heterocyclyl group are each optionally substituted by one or more substituents selected from deuterium, hydroxyl group, cyano group, methoxy group or halogen; Or, R C teeth, [C32] wherein R C Each of them may optionally have 1 to 4 identical or different R c1 may be substituted by Each R c1 each independently, when present, is F, Cl, Br, a hydroxy group, a cyano group, an amino group, a methanesulfonyl group, a methyl group, an ethyl group, an isopropyl group, or a CD 3 , hydroxymethyl group, hydroxyethyl group (e.g., 2-hydroxyethyl group), —CH(OH)(CH 3 ) 2 , -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoroethyl group (for example, a 2-fluoroethyl group), a difluoroethyl group (for example, a 2,2-difluoroethyl group), a trifluoroethyl group (for example, a 2,2,2-trifluoroethyl group), a methoxy group, an acetyl group, -COCH 2 CH 3 , -COCH 2 OH, -COCH 2 C.N., [C33] , -CH 2 CON (CH 3 ) 2 , oxetanyl groups (e.g., [C34] ) or a morpholinyl group (e.g., morpholin-4-yl); Or, optionally, R c1 R may be substituted by C is the following functional group: [C35] Selected from In some cases, Each R 4 each independently, when present, represents a cyano group, a halogen, an amino group, C 1~4 Alkyl group or C 1~4 haloalkyl groups, wherein said C 1~4 Alkyl group and C 1~4 Any haloalkyl group may be optionally substituted with one or more hydroxy groups; w is 1 or 2; Or, each R 4 each independently represents a cyano group, a fluorine group, an amino group, a methyl group, a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, or -CF 2 CH 2 OH, -CF 2 C (CH 3 ) 2 OH, -CF 2 CH 3 or -CH 2 CHF 2 where w is 1 or 2; In some cases, The compound has a structure represented by formula (E): [C36] A compound, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, characterized in that each substituent of formula (E) is defined as described in formula (D).

16. The following compounds and their stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives: [C37] [C38] [C39] [C40] [C41] In some cases, The compound is any of the following compounds: and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates, or isotopic derivatives thereof: [C42] [C43] [C44] [C45] [C46] [C47]

17. 10. A compound according to claim 1, its stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives, A pharmaceutical composition optionally further comprising a pharma- ceutically acceptable excipient.

18. SOS1-mediated diseases or diseases caused by RAS mutations; Alternatively, the SOS1 mediated disease or disease caused by RAS mutation is a cancer or tumor; Alternatively, the SOS1-mediated disease or the disease caused by RAS mutation is lung cancer; Alternatively, the compound according to any one of claims 1 to 16, its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotope derivative, or the pharmaceutical composition according to claim 17, for preventing and / or treating the SOS1-mediated disease, which is non-small cell lung cancer, or a disease caused by a RAS mutation.

19. Use of a compound according to any one of claims 1 to 16, a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug, a solvate or an isotopic derivative thereof or a pharmaceutical composition according to claim 17 in the manufacture of a medicament for the prevention and / or treatment of an SOS1 mediated disease or a disease caused by a RAS mutation, Alternatively, the SOS1-mediated disease or disease caused by a RAS mutation is a cancer or a tumor; Alternatively, the SOS1-mediated disease or the disease caused by a RAS mutation is lung cancer or non-small cell lung cancer.

20. An intermediate compound represented by formula (V), formula (VI), formula (VII), formula (VIII) or formula (IX), and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof, [C48] In the formula, R 2 , R 3 Rings A, X, Y, and Z are defined as described in formula (A), formula (I) or formula (II); R 5 is selected from halogen, hydroxyl, -O-methanesulfonyl, -O-p-toluenesulfonyl, or -O-trifluoromethanesulfonyl, or R 5 is a chlorine or hydroxy group, R 6 is selected from halogen, or R 6 is bromine or iodine, [C49] In the formula, R 2 , R 3 , R 4 , w, ring A, X, Y, and Z are defined as described in formula (A) or formula (I); R 6 is selected from halogen, or R 6 is bromine or iodine, [50] In the formula, R 2 , R 3 , R 4 , w, ring A, X, Y, and Z are defined as described in formula (II); R 6 is selected from halogen, or R 6 is bromine or iodine, [C51] In the formula, R 2 , R 3 , R 4 , w, rings A, Y, and Z are defined as described in formula (III); R 6 is selected from halogen, or R 6 is bromine or iodine, [C52] In the formula, R 2 , R 3 , R 4 , w, ring A, Y, and Z are defined as described in formula (IV); R 6 is selected from halogen, or R 6 is bromine or iodine, and the intermediate compounds, and stereoisomers, optical isomers, pharmaceutical salts, prodrugs, solvates or isotopic derivatives thereof.

Citation Information

Patent Citations

  • Novel benzylamino-substituted pyridopyrimidinones and derivatives as SOS1 inhibitors

    JP2021506864A

  • 2-methyl-AZA-quinazolines

    WO2019201848A1

  • Substituted tricyclic compounds

    WO2021105960A1

  • Substituted tricyclic compounds

    WO2021130731A1

  • Fused quinazoline derivative, preparation method therefor and application thereof in medicine

    WO2021249475A1